International Pharmaceutical Abstracts 1995: Vol 32 Index

675 Pages·1995·288.5 MB·English

Index to Volume Thirty-two
INTERNATIONAL PHARMACEUTICAL ABSTRACTS
January 15, 1995 — June 30, 1995
15 Jan 3200001 — 3200565 15 Mar 3202214 — 3202872 15 May 3204797 — 3205302
30 Jan 3200566 — 3201047 30 Mar 3202873 — 3203466 30 May 3205303 — 3205930
15 Feb 3201048 — 3201612 15 Apr 3203467 — 3204103 15 Jun 3205931 — 3206846
30 Feb 3201613 — 3202213 30 Apr 3204104 — 3204496 30 Jun CUMULATIVE INDEX
SUBJECT INDEX
Numbers education, pharmaceutical, nutrition, 3200966 radiopharmacists, certification, 3200965
education, pharmaceutical, pharmaceutical care, radiopharmacy, 3200891
3200927, 3200977, 3200992 robotics, dispensing, 3200567
1069C85; chromatography, liquid; plasma, tissues, a pharmaceutical, pharmaceutics, vitamin supplementation, ambulatory patients,
mice, 3205680 3201010
education, pharmaceutical, pharmacokinetics, Abbott-72517, see Zankiren hydrochloride
3200971 Abciximab; coronary disease: therapy, reduction in
education, pharmaceutical, Pharmacy Case restenosis, 3205405
Review, 3201039 Abies pinsapo; lignans; isolation, cytotoxic effects,
A ed3u2c0at0i9o5n4, pharmaceutical, pharmacy-nursing, Ab3o2r0i4g6i3n9e s; Cryptococcus neoformans;
education, pharmaceutical, physiology workshops, epidemiology, Australia, 3202406
3200985 bortifacients
AACP, see American Association of Colleges of education, pharmaceutical, Socratic method, gemeprost and mifepristone, comparison,
Pharmacy 3201003 mifepristone and misoprostol; time to expulsion,
AACP meeting abstracts education, pharmaceutical, teaching methods, duration of bleeding, 3201147
alternative medicine, 3200941 009 16 lanosterol derivatives; effects, 3200298
ambulatory care, 3201014 education, pharmaceutical, test kits, 3200884 methotrexate and misoprostol; early, 3201128
ambulatory care, certification, 3200947 education, pharmaceutical, therapeutics, 3200995 9-methylene-dinoprostone and mifepristone;
biopharmaceutics laboratory, 3200889 educators, 3200907, 3200910, 3201005 dosage, abortion, 3202981
calculations, 3200972 entry-level Doctor of Pharmacy, 3200978 mifepristone, 3206060; abortion therapy,
clerkships, ambulatory care, 3200974 environmental health, pharmacists role, 3201008 overview, 3202978; comparison, leuprolide
clerkships, community pharmacy, 3200938 epidemiology, computers, 3200893 acetate, uterine blood flow, 3201917;
clerkships, Doctor of Pharmacy, 3200881 externships, clinical research, 3200998 meningioma, 3205403
clerkships, managed care, 3200952 health policy, 3200908 mifepristone and gemeprost, comparison,
clerkships, surgery, 3200915 Hispanics, U.S. pharmacy schools, 3200940 mifepristone and misoprostol; time to expulsion,
communication, 3200920, 3200962, 3201001 home health care, preceptors, 3200976 duration of bleeding, 3201147
communication, geriatrics, 3200929 hyperbaric pressure effects, 3200831 mifepristone and 9-methylene-dinoprostone;
communication, pharmacy students skills, hypertension therapy, circadian rhythm, 3200649 dosage, abortion, 3202981
3200983 interdisciplinary assessment education program, mifepristone and misoprostol; therapy, 3200115
communication skills, community pharmacy, 3200933 mifepristone and misoprostol, comparison,
3200923 job satisfaction, 3201021 mifepristone and gemeprost; time to expulsion,
community pharmacy, disabled persons, 3200904 joint degree programs, 3200913 duration of bleeding, 3201147
community pharmacy, geriatrics, 3200921 journals, pharmacy administration, 3201043 misoprostol; alone and with methotrexate, early,
computer assisted learning, 3201036, 3201037, literature evaluation programs, 3200960 3201128; labor induction, fetal death, 3206124;
3201038, 3201041, 3201042, 3201044, 3201045 methodology, education pharmaceutical, 3200829 oral vs vaginal, 32
continuing education, 3200951 National Association of Boards of Pharmacy misoprostol and mifepristone; therapy, 3200115
curriculum, 3200922, 3200991 Licensure Examination, review, 3200918 misoprostol and mifepristone, comparison,
curriculum, biochemistry laboratory, 3200888 nontraditional Doctor of Pharmacy, 3200896, mifepristone and gemeprost; time to expulsion,
curriculum committees, 3200898 3200897, 3200901, 3200914, 3200919, 3200936, duration of bleeding, 3201147
curriculum, Doctor of Pharmacy, 3200900 3200963, 3200964, 3200967, 3200968, 3200973, Abortion
curriculum, drug information, 3200903 3200979, 3200984, 3200994, 3200999 gemeprost and mifepristone, comparison,
curriculum, medicinal chemistry, 3200905, nontraditional Doctor of Pharmacy, ambulatory mifepristone and misoprostol; time to expulsion,
3200924, 3200957 care, 3200912 duration of bleeding, 3201147
curriculum, medicinal chemistry, Omnibus Budget Reconciliation Act of 1990, methotrexate and misoprostol; early, 3201128
pharmacotherapeutics, 3200945 3201012 mifepristone, 32
curriculum, pharmacy practice, 3200911 onliiie databases, 3201035 mifepristone and gemeprost, comparison,
curriculum, problem solving, 3200980 online databases, ethics, 3201046 mifepristone and misoprostol; time to expulsion,
curriculum revision, 3200899 patient compliance, community pharmacy duration of bleeding, 3201147
deans, excellence in teaching, 3200987 externship, 3200883 mifepristone and misoprostol; therapy, 3200115
documentation, community pharmacy, 3201013 patient compliance, pharmacy student assessment, mifepristone and misoprostol, comparison,
documentation, long term care facilities, 3200588 00887 mifepristone and gemeprost; time to expulsion,
documentation, pharmaceutical care services, patient consultation, ambulatory care, 3200946 duration of bleeding, 3201147
3200894 patient consultation, geriatrics, 3200961, 3201015 misoprostol; alone and with methotrexate, early,
drug information centers, services, 3201040 patient consultation, handicapped, 3200932 3201128; oral vs vaginal, 3206060
drug information, pharmaceutical education, patient consultation, pediatrics, 3200589 misoprostol and mifepristone; therapy, 3200115
3200892 pharmaceutical care, community pharmacy, misoprostol and mifepristone, comparison,
drug utilization, OTCs, 3200648 3200902 mifepristone and gemeprost; time to expulsion,
education, drug abuse, 3200990 pharmaceutical care, documentation, 3200917 duration of bleeding, 3201147
education, pharmaceutical, 3200882, 3200926, pharmaceutical care models, 3201011, 3201016 Abrus precatorius; effects; schistosomicidal,
3200935, 3200944, 3200949, 3200955, 3200959, pharmaceutical care skills, 3201019 hamsters, 3204650
3200969, 3200982, 3201004, 3201006 pharmacist turnover, predictive models, 3200833 Abscess; antibiotics; breast, therapy, 3200257
education, pharmaceutical, chemical dependency, pharmacoeconomics, postgraduate education, Absorption
3200996 3200939 acetaminophen; amylodextrin tablets, 3205504
education, pharmaceutical, clinical skills, 3201002 pharmacokinetics, communication, 3200906 acyclovir; herpes simplex therapy, skin levels,
education, pharmaceutical, community pharmacy, pharmacy globalization, Mexico, 3200970, 3203618
3200958, 3200988 3201020 adapalene; microspheres, targeting, hair follicles,
education, pharmaceutical, compounding, 3200925 pharmacy schools, Thailand, 3200895 3203081
education, pharmaceutical, critical thinking skills, pharmacy students attitudes, cultural diversity, albuterol sulfate; suppositories, bases, gels,
3200953 3200886 3200205
education, pharmaceutical, databases, 3201000 pharmacy students behavior, 3200942 alcohols, isopropyl; percutaneous, sodium
education, pharmaceutical, drug therapy pharmacy students, demographics, 3200989 carboxylates, 3206196
assessment, 3200930 pharmacy students, dyslexia, 3200948 aluminum; bone cements, 3205076; sucralfate
education, pharmaceutical, entry-level Doctor of pharmacy students, educational outcomes, dosage forms, 3201800
Pharmacy, 3200890 3200934 ‘y-aminobutyric acid; intestines, rats, 3204620
education, pharmaceutical, ethics, 3200993 pharmacy students, leadership, 3200928 amiodarone hydrochloride; interactions, sodium
education, pharmaceutical, gene cloning, 3200956 pharmacy students, organization membership, lauryl sulfate, 3203606
education, pharmaceutical, honors program, 3200937 anthelmintics; physicochemical properties,
3200885 pharmacy students, performance prediction, 32
education, pharmaceutical, hospitals, 3200943 3200832 anticoagulants; interactions, antacids, 3206171
education, pharmaceutical, iearning skills, phencyclidine, discriminative stimulus training, anticonvulsants; new, overview, 3203761
3200828, 3200830 3200737 antifungals; onychomycosis therapy, 3201967
education, pharmaceutical, medicinal chemistry, polymers, coatings, 3200677 anti-inflammatory agents; interactions, antacids,
320098 | postgraduate education, 3200975 3206171
education, pharmaceutical, models, 3200950 protein binding experiments, 3200997 antipyrine; net water flux, 3205691
International Pharmaceutical Abstracts
Absorption Subject Index
antituberculars; AIDS, 3204943 fluorouracil; intraperitoneal, 3205697 norfloxacin; microspheres, in vitro, 3200212
apomorphine; intranasal, SC, pharmacokinetics, furosemide; sustained-action tablets, dogs, nutrition; digestion overview, 3201354
3202118 3202430 oral; models, minipigs, 3203890
aprikalim; sustained-action, 3206628 gastrointestinal drugs; interactions, review, pefloxacin; interactions, aluminum, combination,
aspirin; myocardial infarction, pharmacokinetics, 3202415 magnesium antacids, pharmacokinetics, 3203608
3202105; sustained-action floating capsules, glycine; toxicity, cerebral edema, nausea, 3205086 pentazocine; percutaneous, in vitro, methodology,
3206202 gonadorelin; percutaneous, iontophoresis, 3203648 3205199
atenolol; tablets, generic equivalency, 3204297 horseradish peroxidase; rat colon, enhancer peptides; oral, barriers, 3203668; peptidase
baclofen; interactions, -y-aminobutyric acid, rats, effects, 3203069 distribution, 3200383
3204284 hybrid (BDBB) a-interferon; buccal, rats, phenolsulfonphthalein; mucosal, absorption
benazepril hydrochloride; colonic vs jejunal 3206204 enhancers, 3205506
administration, dogs, 3206188 hydrocortisone; percutaneous, dodecyl-N,N- phenprocoumon; pharmacokinetics, 3202116
benzoic acid; percutaneous, oleic acid, 3202438 dimethyl-L-alanine, 3201406 phenylalkylcarboxylates; rat intestine, 3206191
bumetanide; oral, pharmacokinetics, 3201803 hydrocortisone acetate; percutaneous, laurocapram phenytoin; availability, emulsions, rats, 3206206
2-butyl-1-[2'-(1H-tetrazol-5-yl)1,1- biphenyl-4-yl]- derivatives, 3203635 phenytoin sodium; skin, topical wound therapy,
methyl-1H-benzimidazole-7-carboxylic acid ibuprofen; lozenges, dogs, 3203075 3200182
esters; availability, rats, 3203068 (+)-ibuprofen; enantiomers, bioinversion, phosphocitric acid; oral availability, rats, 3200198
calcitonin eel; pulmonary, protease inhibitor pharmacokinetics, 3205702 phosphorus; toxicity, 3205383
effects, rats, 3205494 (—)-ibuprofen; enantiomers, bioinversion, pipemidic acid; microspheres, in vitro, 3200212
calcitonin human; rat colon, enhancer effects, pharmacokinetics, 3205702 piroxicam, percutaneous, rat skin, fatty acid
3203069 iloprost; oral dosage forms, pharmacokinetics, effects, 3201794
calcitonin salmon; nasal, enzyme inhibitor effects, 372 polyethylene glycol 4000; rat colon, enhancer
rats, 3202420; nasal sprays, 3203621 indomethacin; ester prodrugs, percutaneous, effects, 3203069
capsaicin derivatives; percutaneous, in vitro, 3203657; percutaneous, dodecyl-N,N-dimethyl- polyglactin 370; nanoparticles, body distribution,
3200373 L-alanine, 3201406; suppositories, availability, mice, 3203065
ccaarrvbeiddiolpoal;; ardemviineiws, tr3a2ti0o6n6 22r outes, rats, 3203888 in3s2ul0i1n2; 22i ntranasal, lysophospholipid effects, pomliycgrloascpthien re3s7,0 , tacrogmeptianrgi,s oinn,t esptoinlayls tyMr encee;l ls,
ccceeelffitipixrbioumlteoe;ln ;; miebnlttoheosodtdi,on allou,rg iynr,ea ts,l3 e2v30e2l5s07,36 8838 230 6607 33mo22d00e65l64s08,17 ;; rambmbieicttrasob, oelm3iu2sl0ms6,i6 o7n8rsa;,t cororalatlos,,n 33e22n00t56e4r19o8c73y;;t esn,a sal, po33l22y00s60t2y3r08e82n; e ; naGsIa,l , pamritcircolpeas,r tilcylmesp,h oirdat s,u p3t2a0ke6,2 11ra ts,
cimetidine: intestinal transport, mechanisms, rats, percutaneous, iontophoresis, in vitro, 3206198; polystyrene, comparison, polyglactin 370;
3205692 rectal suppositories, absorption enhancer effects, microspheres, targeting, intestinal M cells,
cinnarizine; GI transit, magnetic tablets, dogs, 3200187; suppositories, sodium salicylate, 3200382
3205137 3205510 pravastatin; pharmacokinetics, review, 3206612
cinoxacin; microspheres, in vitro, 3200212 insulin human; duodenal, 3200371 prednisone; oral, bioavailability, metabolism,
CL-275838; pharmacokinetics, dosage, 3202650 insulin-like growth factor I; metabolism, rat colon 3200184
clindamycin; bacterial vaginosis, intravaginal enterocytes, 3206601 propranolol, comparison, celiprolol; intestinal,
therapy, 3203750 interleukin 2; sustained-action injections, rats, rats, 3203883
claovfaailzaibmiilniet;y, dpoisgasg, e 32f0o3r0ms6,6 ; eqeufifvecatlse,n cmyi,c elles, it3r2a0co1n7a8z4o le; interactions, didanosine, 3203059 praobpsroarnpotliooln heyndhraoncchelrosr,i de3;2 00p1e9r3c;u tapneerocuust,a neous,
3201814 ketoprofen; interactions, omeprazole, 3205482 iontophoresis, 3203077
clonidine; percutaneous, dodecyl-N,N-dimethy]-L- ketotifen fumarate; percutaneous, transdermal proteins; oral, barriers, 3203668
alanine, 3201406 patches, 3203078 protirelin; intestinal, transport mechanism,
codeine phosphate; release, ion exchange, kinetics; lymph/blood partitioning, models, 3205695; intranasal, enzymatic stability,
3204306 3203889 3204349
colony stimulating factor; complexes, lanreotide; intranasal, in vitro, 3200818 radiation; UV, plant extracts, 3202676
pnaoslayle thpyrelpeanrea tigolnysc,o l,r apbbuiltmso, na3r2y0,3 61ra5t s, 3203879; leeunchiannec eernsk,e ph3a2l0i5n1;3 8t ransmucosal, absorption ra3n2it0i5d6in9e2; intestinal transport, mechanisms, rats,
ccyrvmcoieltmtoroohsl,op yodnr3o il2no0seg2o;y4 d,3i 7pue m3r;2c 0u5tp2ae0nre1co;uu tsa,pn ehoalurismp,ao csooikmoiennste,otp ihcosr,e sis, in llleee3nuvve2poto0 rtd0ohow2lypai0ratd2o;eex; r i naaedsfcl;meuut isxanp,tiie ensn;t3ts e2rira0ooart5cnai6t loi9,no a1 ne fsro,ro rosumostuleuslsc,a,r t aildrofoaangtt sse,,, e f3f323e2c02t030s481,387 0872;1 rrRuiOsfy-uai4smjp2pie-innn5hs;8ui a9on2nig;sn t, e srpaarhnce;atc rioomnpnasesctr,ioc tkuuifttnoaioenodten,io, c uss33,,22 006e301f227f00e0c07;t8 s1, 7 3206804
microemulsions, 3204313 salicylates; topical, interactions, anticoagulants,
ddeetsimroelpirxe ssacient;a te;n asalli,p osaonmimeasl,s ,d o3gs2,0 54392203 064; li3b2en0z6a1p8ri8l ; alone and with soybean oil, rats, sa3li2c0y0l1ic7 8 acid; dermal, phenylephrine effects,
pulmonary, dogs, 3203620; pulmonary, sheep, lidocaine; dermal, phenylephrine effects, 3205701 3205701
3203619 liatdhmiiunmi stcraartbioonna,t e;3 2p0o2i2s8o4n ing, intravaginal silibinin; cholestasis, effects, 3202675
ddieccxollaoomfnee,tn ahcia;ns ovnpiteerr-ocB,u -tD3a-2ng0el1ou4ucs5,1u rotniissduee; lepvrelosd,r ug3s2,0 26ra0t5 mMaE3n-2g10a20n04e71s4;e ecxhcliopriiednet;s , gagsatsrtoriinct easctiidniatly,, emfofdeecltss,, ssiosllvyvenernd trsso;um lefp,ae drica3zu2it0na1en9;e 5o2ut so,p icailn, viSttroe,v e3ns2-0J3o6h4n9s on
dircalbobfitesn,a c 32h0y0d3r8o5x yethylpyrrolidine; transdermal, 3203278 so3m2a0t0r1o8p1i n; nasal, didecanoyl-L-a-lecithin effects,
didanosine; percutaneous, rats, 3205499; mebeve1r8i04n e hydrochloride; bioavailability, sulfamethoxazole, combination, trimethoprim;
dipgeorxmiena;t ijoenj,u norastt oimnyt,e sti3n2e,0 6630220 1785 meetn-heannkceeprsh,a li3n2;0 5t1r3a8n smucosal, absorption suilnftoenryalcutrioenass,; aisnctoerrbaicct ioancsi,d , an3t2a0ci1d7s8,3 3206171
dihydroergotamine; intranasal, rats, 3205694 tacrolimus; ointments, 3202339
methotrexate; percutaneous, microdialysis,
divalproex sodium; chronopharmacokinetics, 3203881 temarotene; oral, effects, drug delivery system,
3202653 methotrexate derivatives; percutaneous, 3204672 dogs, 3201822
drsuygns;d roamdem,in isretvriaetwi,o n 32m0e0t3h8o0d;s , eqsuhoirvta lebnocwye,l me3t2h0o3x9s2a2l en; dogs vs in vitro, methodology, te3r2od0i6l1in8e9; bioavailability, body distribution,
methodology, 3203926; human vaginal mucosa, metkephamid acetate; colonic, rats, 3205689 tetrylammonium bromide; transport, iontophoresis,
m32e0t0h1o8d3o;l ogmye,m b3r2a0n3e3s0,5 ; meicnhjeacntiisonmss,, re3v2i0e6w6,2 0; meftoorpmrso,l o3l2 0t6a1r8tr5a;t e; titmaer gectoinntgr,o lcloeldo n,e xpdloossaigoen thmeeotphhoydlloilnoeg y,a nh3y2d0r3o3u1s;2 food, fat effects,
models, methodology, 3203923; overview, systems, dogs, 3206210 3200673; sustained-action, dosage schedules, °
3205526; percutaneous, in vitro, 3203649; metronidazole; bacterial vaginosis, intravaginal 3201801
percutaneous, lipophilicity, 3202120; therapy, 3203750; multiple vs simple emulsions, tiaprofenic acid; pharmacokinetics, enantiomers,
percutaneous, menthol effects, 3206195; 3201796
percutaneous, (—)-menthol-ethy! alcohol, micelles; correlation, lipophilicity, 3206675 ticlopidine hydrochloride; sustained-action,
3201225; permeation kinetics, intestinal mitomycin; intraperitoneal, 3205697 availability, 3204310
epithelium, 3205693; rate, bioequivalence models; cosmetics, pig skin, 3202126; everted timolol maleate; percutaneous, absorption
studies, methodology, 3205770; rate calculations, intestinal rings, 3202655; Gi, 3205783; skin, enhancers, 3200193
3206695; sustained-action medications, 3-layer vs single-layer, 3206673 triamterene; solid dispersions, dissolution rates,
pharmacokinetic models, 3201824; monoclonal antibodies; iodine I 131, yttrium Y 3204304
toxicokinetics, 3200803 90, targeting, 3200153 valproate sodium; chronopharmacokinetics,
estradiol; percutaneous, nonionic surfactant morphine sulfate; dyspnea therapy, nebulizers, 3202653
vesicles, 3203651 3203135 valproic acid; pediatrics, 3204307; review,
exalamide; laurocapram effects, rabbits, 3203070 nafarelin acetate; percutaneous, 3202423 3202007
flavones; percutaneous, M. chamomilla, 3206617 nalidixic acid; microspheres, in vitro, 3200212; vasopressin; microemulsions, rats, 3206183
fluconazole; pediatrics, 3204623 solid dispersions, 3203105 xylooliosaccharide; lack, health food, 3205629
flunitrazepam; intranasal, abuse potential, naloxone; therapy, opiate dependence, nasal zidovudine; interactions, food, 3205130
3206634 sprays, 3206157 Absorption enhancers
fluorescein isothiocyanate; buccal, bile salts, in nimodipine; enhancers, 3205536; fetal, maternal, acids, fatty; alveolar permeability, mechanisms,
vitro, 3203062 3206126 3203886
1096 International Pharmaceutical Abstracts
Subject Index Acids, fatty
alcohols, dodecyl, comparison, dodecyl N,N- sodium lauryl sulfate; sodium nonivamide acetate, spheres; he genrm cellulose microcrystalline,
dimethylamino acetate, laurocapram; percutaneous absorption, 3200373 properties, 320002
propranolol, timolol percutaneous absorption, sodium salicylate; effects, insulin rectal suppositories; pon Sea blood levels, 3201797
3200193 absorption, suppositories, 3200187; insulin sustained-action; release, 3200686
alcohols, ethyl and (—)-menthol; percutaneous absorption, suppositories, 3205510 tablets; granules, compression, 3205033;
drug absorption, 3201225 sodium taurocholate; insulin nasal absorption, maltodextrins, 3203678
alcohols, lauryl, comparison, dodecyl-N,N- models, 3206678 therapy; interleukin 2 toxicity, 3206131; overview,
dimethyl-L-alanine; drugs, percutaneous sodium taurocholate and glyceryl monooleate; 3204472
absorption, 3201406 effects, calcitonin human absorption, rat colon, toxicity; abuse, symptoms, 3200102; com isons,
amides; synthesis, effects, 3206511 3203069 3205348; headache, combinations, 32
aprotinin; effects, calcitonin nasal absorption, rats, sodium taurodihydrofusidate; calcitonin salmon liver, overdose, 3203536
3202420 nasal absorption, 3203621 utilization; pediatrics, U.S., 3201129
bestatin; effects, calcitonin nasal absorption, rats, Abstem, see Calcium carbimide citrated Acetaminophen glucuronide; metabolites;
3202420 Abuse; drugs, see Drug abuse acetaminophen metabolism, phenobarbital effects,
bile salts; enkephalins transmucosal absorption, Acacia; complexes; gelatin, microcapsules, oil models, 3200432
3205138; fluorescein isothiocyanate buccal uptake, 3205525 Acetaminophen sulfate; metabolites;
absorption, 3203062 Acalypha torta; effects; antibacterial, in vitro, acetaminophen metabolism, phenobarbital effects,
camostat mesylate; effects, calcitonin nasal 3203906 models, 3200432
absorption, rats, 3202420 Acanthamoeba keratitis Acetates; buffers; cromolyn percutaneous
capric acid; phenolsulfonphthalein absorption, chlorhexidine; combined therapy, 3203770 absorption, iontophoresis, 3202437
rats, 3205506 neomycin; combined therapy, 3203770 Acetazolamid le
didecanoyl-L-a-lecithin; concentration, effects, polyhexamethylene biguanide; combined therapy, glaucoma; overview, 3205603
somatropin nasal absorption, 320018 3203770 polarography; spiked serum, 3203858
dihydrofusidates; enkephalins transmucosal propamidine; combined therapy, 3203770 solutions, ophthalmic; 2-hydroxypropyl-B-
absorption, 3205138 Acanthospermum hispidum; and Cajanus cajan; cyclodextrin effects, rabbits, 3205135
dime0th3y6!8 1s ulfoxide; dopamine body distribution, Acaabonrtthiuves eiflfieccitfso,l iutse;r at2o-gbeennicziotxya,z o3li2n0o3n9e0;2 AAcceettiocg enaicinds;; efXfyelcotsp;i a liamruolmuast icteas;t s, ispoHl,at i3on2,0 4114
dodecyl N,N-dimethylamino acetate, comparison, leishmanicidal effects, in vitro, 3205618 cytotoxic effects, 3202128
alcohols, dodecyl, laurocapram; propranolol, Acarbose Acetone
timolol percutaneous absorption, 3200193 diabetes mellitus; non-insulin-dependent, therapy, comparison, alcohols, ethyl, alcohols, isopropyl,
dodecyl-N,N-dimethyl-L-alanine; drugs, 3205095; therapy, 3206426; therapy, side effects, combination, chlorhexidine gluconate,
percutaneous absorption, 3201406 3203821 trichlorotrifluoroethane; skin peels, degreasing
edetic acid; intestinal permeability, rat models, Accidents agents, 3206449
3205760 alcohols, ethyl; decrease, England, 3205222 a dimethyl-B-cyclodextrin, 3203679
eggflla33i3mefi3v333yyfbieno2e222222ccftcssn0t00000e0oretuot5h62r460ofcs3lro,ty4;o14u3i210pp s lnr9d49409t6h, o4o883945io c9l;l;;;2;;oratm ;c on le 0ro ac,sag0nlcid aniknlye8cotsrr-saeif,i1oropi,funotm ta8onlen rgoomtoric tees pdno3tnt,3eoairi,s l2 ttr2tn,o pr0yif0 3efpiad3ne2i2 ennuerp3 ho4s0ne lro1nup3a5 ,onmp2tonm7ti4 oero;pdin;a9trnp ert 3 b9n,hcearru2 ; olsuairmdc0 irnntoeyiicns5eaaadadoa udssb5nitnlalaris3enuiit nalsuoaon6oomb o,rg,saupsn s p abhaso,itlsobdr t nisi orespankeorleo atumia npisrnbirbvo,vt,ipsoois pue itstoncoesrro,ir,hrr3oryen oap op,2,ct, ntl t 0u ,iai1tc sotosrok8aneknaiiln3i,;,tnnons e0 , n,,o; ,u s AAAAAAAcccccccghspcatcccc-eeenothooporrurDbxacaammrilieplienuarpaoecayrdd-dtmitaipst aiiSiaorntrhierltoticlyiisyh,dc,laia;o;dsles s s,tt laaeo;;t iil xsd nsbsotoeiee,sl;thenhnesre ro ,oemao feamIcQsdfMnatpeCu iC3areaocI irle2c,lln;-nao i0eoh pua2asv0geprleap0cJ6airitlr4llael3cisCit;d2 e,ra5Ah i ls1lm c, fH9 ee3t o cnlOo2hrra3drl0 yres 2oe4adH,0,cs5ss r 5oteti9o ima3a 35cogn22e nheds00s l ao,24ro kd19Cdrii89sa3id,6u8r2dn , me0ee 33 y5 23402f540a i75l00u00re 8 4ANAANNN-c-c--c-3s33K31AAeeAAepA2,222Btcccte3ctc0000-yeeec,o ye22532l4ttttpl6t668-a6ryyoh33ay7t 7otl8lxe77h2lmmi7 3yni e aio - otodntmn2rdnir ro-yiipei-(,apesnb 4zep;oeo-pt 3nlgntmi2eiezied—0ds;tye 1e; hl 4 i amsavdmeyme iitnindaptdbeheheoeis-d ssle;2;; iis -sty t,aelrl s)lumis;icbpip3pt oen2oupcpro0Lhthei6C-isrl,55l,oi 4i -cmc8hiRepiiNt t-latyzrMaym;oy;sl eR ;emr, ai icn,nsda deepexrstx,eu,oe m -,
HPE-101; methotrexate percutaneous absorption, toxicity; dermatological reactions, 3203545 ph3a2r0m4a4c7o0g enetics; polymorphism, mechanisms,
3203881 Acenocoumarin, see Acenocoumarol
2-ahbysodrrpotxiyodne, carnaotsi,c 32a0ci5d5;0 6p henolsulfonphthalein Acpernotohcrooummbairno lt;i me,i nt3e2ra0c1t7i7on7s ; mianserin, suclyfstaimce thfiobxraozsiosl,e ;3 2b0l2o6o9d2 cells, in vivo correlation,
3in-adhboysmoderrptothxiayocdnie,n c;a rnatohsiy,cd r 3o2ga0ecil5ds5;,0 6p ohpetniomliszualtfioonn,p ht3h2a0l6e2in3 9 AAccaeentotinab,ma citdseeoreic aelPp ehreaiflfneodcostpsp,ro irl3a 2n0i4c5 55a cids; synthesis; AAccaseenytttmyiypdliaocctthyehosselt;cie ntiaenoc;eme yt,ta emsti3sn2; o0p2ph9ate9in3e ntp osiesloencitnigo,n, 3201854
isionp rvoiptyrol, m3y2r0i5st1a9t9e ; pentazocine skin permeation, Accoemtbaimniantioopnh,e ni buprofen; dosage forms, se3p2t0i2ce5m0i2a ; cytoprotective antioxidant effects,
ketoprofen; mouse skin, 3200195 chromatography, 3202096
llaasrp3uuaeu2rrbnpe0boept3itocht7rs asai7p,9tt6 r;ioa or3meni2;f,e0 f s3e,c0e3 tf72sf030,e; 2c6t 02is05n,e19s fu;8fele 7xic ntas slt,arr meactmituidamcel o ncaaabobzsrsoonolrerpeput tmii,oo nn,,e ffects, ccccooootmmmmomepxpptmiaaahcorcrioitintdsyis o,oool nnnco,;,kog l iydd,d;ean i nnecetytlr3ih og2-eyffi0r,eaan3 nipf0laylsuc0,tra;0 rem e, mps oeassd 3ttio2euar0otny2arl ri9otc4ahsad3r,gi i entngi3ts,s2 ,0 1t3h3a2es10pr65ia rp6iy6n,9; 4aAN-c--afAeAAaccittcclieyeeuvtltritydetyy,ylill ,fgd -eooiBn3xvg-tei2oDran0xvn-;6iiy gn5ell,4wp u 9,hc dosoeet3sero 2aid0vmeAa1icct3noei7imtv1dpye aolss;ds iietg;sio yoxnnitte,nhse tssi;3 s2;0k i6sd3tn1re0uyc ture-
laduordoeccayplr amN,, N-cdoimmpaertihsyolna,m inaloc ohaoclest,a ted;o dpercoyplr,a nolol, co3m2p0l5e0x3e0s;; xBa-nctyhciinoedse,x tsrtianb,il itpyo, wdseolru bicloitmyp,a c3ti2o0n0,2 50 Aciestonyilahzyidd,r az3i2n0e3;2 73m etabolites; aconiazide vs
latuirmoolcoalp rapme,r cuctoamnpeaoruiss ona,b sodroptdieocny,l -N3,2N0-0d1i9m3e thyl- ccroynsctoalmsi;t ahnatr dntehesrsa pya,n is3o2t0r0op1y4,9 , 3230230645135;7 tableting Acmeehtteyaplbaiotlsoiottnoeixsia;cz iitday c,o ni3a2z0i5d1e8 6v s isoniazid, 3203273;
llleyapa3Lrusuan-e2optriarls0eoml,cep1 aaccut4lniait30sitnpa2,nh6srn0ie ;aen;2 mo;3 4u e22dsf0d0dfr 5eee ucr4gsatis9bmsv,s2o,a o ptrrpicpveeatesrlisccso;iuin ttn,oa hnnyi3endn2aor s0uoan3scla 6o sr3aaat5lbbi sssooaorrbnppsetto iiroopnnt,,i on, dddgiioirnk3fstasi2fesnanur0ougesal0lteicuai3;ottct7 niisi4;o,ooo ;n nnvs sea;a;r gcer dattaaoitrhtlevsyooscales;pot ,e -hi asoosllpnogicsr lseo,aislh ayduson e, leas dtsl,f3hi, ylys 2sul3pi0i,efs2d1 or,0i2os pz27dieh33,o9da 1n2 rs20lm,b 2ia ev8cde9o3,r5 k2 i0t3no62xe20it6c2ii22ct 3sy,2, AAANAcccc-gfeieheAltcortlcylsiyoesloal,rttsv rshaiyiplry3lci,id2psc r,r0 y ai6slmae43iey;9c2 c 6 0iA 2adnc6ci;y4ig cd8ol,x do iovnssi;ear e, g pesAeh sea pfroimArracmicesnoc; ka iinmneeitddiiecc sa,t ed dental
menthol; effects, drug absorption, 3206195 3203537 a ,-Acid glycoprotein
(—)-menthol and alcohols, ethyl; percutaneous metabolism; phenobarbital effects, rat hepatocytes, binding; drugs, affinities, UV spectrometry,
drug absorption, 3201225 models, 3200432; rats, 3205703 3200389
nafarelin acetate; skin, 3202423 metabolites; interactions, omeprazole, 3204293 fluorometry; blood levels, 3203835
ol3ei2c0 2a4c3i8d ; skin, fluorescence spectrometry, microsphe2r es; concentration, effects, release, Acaildu-mbiansuem , imcboamlbainnactei on, magnesium; antacids,
phosphato-dihydrofusidate; leucine enkephalin osteoarthritis; therapy, 3205578 chronic therapy, toxicity, 3202946
permeation, 3201232 overdose; therapy, 3205609 streptomycin; adverse reactions, 3200067
sesquiterpenes; fluorouracil, structure-activity overview, 3201356 Acidic fibroblast growth factor; wound healing;
relationships, 3201253 pain; therapy, circumcision, neonates, 3202393 diabetes mellitus, mice, 3201396
sodium carboxylates; percutaneous absorption, pharmacokinetics; space flight, models, 3202149 Acidifying agents
3206196 poisoning; overdose, toxicity, patients knowledge, acetic acid; limulus tests, pH, 3204114
sodium cholate; effects, insulin rectal absorption, 3203535; therapy, overview, 3201854 hydrochloric acid; therapy, central catheter
suppositories, 3200187 poisonings; antidotes, 3205342 obstruction, 3204453
sodium glycocholate; effects, protirelin nasal prescribing; cancer pain therapy, 3205470 Acids, fatty
absorption, 3204349; lanreotide intranasal release; amylodextrin tablets, 3205504; pellets, and polysaccharides; supramolecular biovectors,
absorption, in vitro, 3200818 3201276; suppositories, 3204311 3203677
International Pharmaceutical Abstracts
Acids, fatty Subject Index
Colchicum ritchii; isolation, 3200406 education, pharmaceutical; students attitudes, Actifed, see Pseudoephedrine hydrochloride;
concentration; cell cultures, 3206686; effects, 3204023; students, survey, 3204033 combination, triprolidine hydrochloride
clofazimine micelle solubility, 3201814 epidemiology; M. avium complex, 3203711 Actigall, see Ursodiol
corn oil; atopic dermatitis therapy, 3204220 erythromycin; whooping cough therapy, 3204244
docosahexaenoic acid, combination, foscarnet; cerebrospinal fluid penetration,
eicosapentaenoic acid; kidney failure therapy, 3200375; cytomegalovirus retinitis therapy, Actimmune, see Interferon gamma-1b
cyclosporine toxicity, 3203547; long term overview, 3202035; interactions, ciprofloxacin, Activation analysis; acetaminophen; crystals,
therapy, toxicity, 3201667 toxicity, seizures, 3200161; therapy, toxicity, tableting kinetics, 3202895
dodecanoic acid; effects, piroxicam percutaneous seizures, paresthesia, 3202302 Active Implantable Medical Device Directives;
absorption, rat skin, 3201794 ganciclovir sodium; cytomegalovirus retinitis, regulations; medical devices, adverse incident
effects; alveolar permeability, mechanisms, 3205514 reports, 3203329
3203886; —— percutaneous absorption, rat gene therapy, 3200743 Acupuncture; review, 3206790
skin, 3201794 globulin immune; bacterial infections therapy, Acyclovir
enemas; short chain, compounding, 3201242 pediatrics, 3206317 and anti-infective agents; infections prophylaxis,
erucic acid, combination, oleic acid; interleukin 2; therapy, 3205155 3203031
adrenoleukodystrophy therapy, 3202582 intravenous therapy; home, rural areas, 3201009 blood levels; valacyclovir prodrugs, availability,
esters; etoposide, teniposide, emulsions, 3201840 long term care facilities; consultant pharmacists 3201450
evening primrose oil; atopic dermatitis, effects, role, 3204063; pharmacy services chickenpox; costs, 3205582, 3205583; therapy,
fi3sh2 0o1i1l;9 2a topic dermatitis therapy, 3204220 medgolcuummeinntea;t iolne,is hm3a2n0i0a5s8is8 therapy failure, 3to2x0i0ci7t6y4,, 32302209335538 ; therapy, prednisolone
gHppmssPsuayaksauleoa333lleirrlpemrdbii22;2neimpuoipsip 00nsi0orilocouttt1s5od5pdmreimeii it1h77ipenur cctius93l3tdima olse2ii6i6loc ir aop caal c isnccoeiicepeii,atnsnoassuddty uoarc;;l;;e,tmial ; mrrdle a io;ledeest3t nfoff r,ami2fffaig yoiaseee0drenc ktccce6ni;3eiotttss t6unl2psssk;s,l,s7,,i0id , e c;50ne s 37nfpfi,pile62di ntnuchme80rhdieiaraa;eo1domembtrri x7manasitami9ettcyocpsaciity4,riytca t,ch a,pdiom iba tassi ldciltt,l3aoi orih pl2gtnnaee y0ey te rr,ff2u,a fecfvmp0 aefesu y3v1fcc t,a3e2tt6cia css20 lnt,o,01a3s erb30,2oni 070ule344isut 6 2my 3, 5 opmppppppaceahheehfrP333ttdtaanoa.ga22i2r2iirli rtlreeae0000elmcmatnonum,u445a2aamrttt rrma71c29ci ieiiic3i798c2,dendces nso2ei8767uiad;ti;e0e t rn3u s e0c iec2,;c5popa d0 aa2tnnin4nliia0leoeh1ts rooo umu9iernsnmimtm8hcp;gohcooaei inrtnasnoetai ca;in;letao aa;tre,mt hmc;e dme j ,orpruo 3cmaurnlba2pogmceir yp0 uoie,teh6 mnsr xyy1ahpilc f2t3mataahia72rcxayponi 0iinnh lis1siigaao,7nterpsi ng0m,hie,,4aa ss 3 , c r2 Aim3a0utsap2ts5htch0toe4siar5vr2 sra2aa2tlm2qpris auyo0a cl o ,ien r,soe tl;se , Accchhphirtyoyeeonehea3tpr33lxtrrmvrtadher222ieaipppproevmoc00r0teeeemamriipia16wi1sssaraeenthc,13 o c7pwyiigyt 4ny7i;,7ssilasgz 0,;s 0otoa0eloi3 ;t nrnx sn com23ss itai,sopv02;tBe;tsk lmi6 ar0t- i,iearl;2h4eon fxiz ,us8en4 nas;i usr1a36 m;n dlr am 24eceo3vpiruil;0vev2tiyonrcee 2yuhnu0 oallu,9deftsln0okt eerfi9,giv6hesaca n4iti3ei0m,tpea rrlr 32iiy9,,u;iaoa2,0 r3 pln ,05eyes2e ,H73h,;3s0 y56I e ;2t1ern71V 0r r7tep 8a 4eh4odepn 3ve2insrspir7sa oprea9etldowpza;eaug,yoss ncr ,se,tte ts tas3se,ht,s2r e3i i 0ro2o1an3t0n9p,h25,y 9e 40,r14 0a 7p3A;y1I, 6D S,
Acinetobacter baumannii; resistance; anti- programs; pharmaceutical industry, WHO, 3B-Acyloxy-3a-methoxycarbonyl
infective agents, 3200822 3204764 synthesis; structure, effects, 3201408
Acinetobacter infections pyrimethamine, clindamycin and sulfadiazine; T. Acylphosphonate thiosemicarbazones; synthesis;
anti-infective agents; resistance, 3200822 gondii myocarditis therapy, 3204225 antiviral effects, 3201404
polymyxin B, combination, sulbactam; topical research; European Union programs, 3202753 Adalat CC, see Nifedipine
Acitthreertaipny , 3203140 riifnafbeucttiin;o n Mtyhceorbapayc,t erreivuiemw , av3i2u0m1-9i3n6tr;a cellulare AAddaalpaatl enReet ard, see Nifedipine
comparison, etretinate; psoriasis therapy, 3200155 mycobacterium infections therapy, 3202517 comparison, tretinoin; effects, epidermal, 3201372
lichen nitidus; therapy, toxicity, lack, 3204227 risperidone; manic disorder therapy, 3203001 microspheres; targeting, hair follicles, 3203081
psoriasis; therapy, overview, 3201971 sulfadiazine, clindamycin and pyrimethamine; T. Addiction, see Dependence
Acne gondii myocarditis therapy, 3204225 Addicts
isotretinoin; therapy, cost benefit analysis, sulfamethoxazole, combination, trimethoprim; attitudes; methadone programs, Netherlands,
01330 Nocardia infections therapy, 3204221; toxicity, 3206796
therapy; review, 3206402 3205083 cocaine; crime, survey, 3204755
tretinoin; therapy, 3204968 tests, laboratory, 3200281 compliance; buprenorphine vs methadone therapy,
Acne vulgaris therapy; bacterial infections, review, 3205633; P. 3206136
erythromycin; gels, effects, 3200691 carinii pneumonia, 3206418; P. carinii diacetylmorphine; morphine levels, hair, 3203240
erythromycin, comparison, OPC-7251; therapy, prophylaxis, 3205103; infections, review, drug abuse; legalization, attitudes, 3201581;
3202984 3202558; intestinal cryptosporidiosis, 3201948; needle exchange programs, 3201531, 3204742;
minocycline; therapy, toxicity, melanonychia, Kaposi’s sarcoma, overview, 3202027; therapy, relapse, 3200493; therapy, women,
AAAccCO3ooP2N33nnC022Uii-300ta,27i42z 72n19i3e558ds ;19e4e e,; pNocciioosmmmouppnsaaitrrniiignss;e oo nnr,,eh pyoeidrstrrosyon,tci hhar3zloi2odm0r;y1i c6dia5env0 ;a i latbhielriatpyy,, UzanohoM3lipvyy2ctpeipc0eorteo0drvar0b tbii4uaieKnnm9cweii,m t;sn ue tgnri3dteic2ho ,u0em mr3i; a1n 3pf5y2ie9c,n0c,l ft1i ein8Fcoi83tnDci72 aAo0l n p 5sr5,pao7 php4pha3;ryr2 olm0vaap1axac1lissy4ss,,9 i ;vs e33e r22v00i26c74e41s,39 ; mstyhepb3pretaar2irrthe0nariavgpi5edeeeyn8rons;t3s;tn ,5 ie sp o;aernm lno eedgtct prhthreianoooremdngae o,prd ylall,omee3 gs n2y,gd0st ,i2hh aa7,rcr 9e3ei9v23nti;2g0ye ,00lw 64m,t8 Ao2hu0re03s1pr t2;ahr0p ia6ynl8r eie0a pl0,ra ;aepb fs3uee2sr e0e,2n 8ce0s0,
AAccpaqoolriounesvipiouortndreutiidsmnn, ge ;;i s3mp2Ctme0hhcu1eiinr6neao5espds0 yee , f iohcveirebersvn,ic eywt o,x isc3yi2tny0d,1r 6o37m29e0 4163; zzzaaia3lldn2ccoaii0vltt3yuaas5dbbi5iiisnn7n,eee , ; 3a2cnp0odh3m ap9rza8mir0adi cosovokunid,ni entezi;ic dsot,vh uedrliaipnvyeer,; dctiohsseetra sabepesyn,,e fit Adeidfnatifjhmeteecicitrftvsaoie;pos sent suni;tin itecr a odfiscunoorcramopnmmttpiuoaonitnnii, bt iyrlc eioltnepitareassoie,gn, re ra33sm2,2s0 0,43 396233701202;0 4 68759;5
aaaannnt3Pttto.i2iiv v0t0hcaiu42aerqb4ram9ueil6o5orns4p6icn;;hiu e il,hal ptreinhsrccee;p or uemasmfppta oayucn,rbgt ioeeirnrasg;ic,oe tu nralip,loua3 isrt2siir p0tistey6c ,hsn1 ,ett2 rhar7aeem3 rpli2ayad0pt,iiy3 on,1nr e6,e 63v i2ime0sowe4r,tt9 ha4il3oin tayt,e ; Aczzqiia33ddun22ooai00vvlr23uyues6d5ddii55is n4n7,ee i, m 3ma2cnu0odn3m o9pdz8aae0rlf icsiiotcanib,ei nnecz;ay l ctihsteyarbnaipdnyer,;o mcteohs etr vaabpceycn,ei fniets ; aapc3cgnehi2etfop0niros0tohtp2sfeih,4lmaa 0omto;x ep3 a,h2ci i0cinl4ancii8ro ncb0mc o7piopa;nmfltcp aaioactbmtatiipiozlnrabt,i tir tilesibi3oteita2nslib0a,ieim 4tsl,ii,9t3e 3ys26,p,03 ;a 62 rL033eC40an2,n95t0 t3;e3ir2 36na;29el 0o3 3p;cln2 aua5ltsc6rctl;iiiit ucnii moc na,l
ciprofloxacin; interactions, foscarnet, toxicity, clinical studies; investigational services, 3204810 pharmacy services, 3200061; compounding,
seizures, 3200161 Acridine; complexes; B-cyclodextrin, solubility, labeling, ethics, 3203359, cyclophosphamide-
clarithromycin; Mycobacterium avium- 3201302 ondansetron incompatibilities, 3204346
intracellulare infection therapy, pediatrics, Acrinol, see Ethacridine lactate equipment, filling pumps, 3205974; esmolol,
3204240 Acrivastine; combination, pseudoephedrine; hay incompatibilities, containers, vehicles, 3200717;
clind yci ine and sulfadiazine; T. fever therapy, overview, 3201317 etoposide, incompatibilities, containers, vehicles,
gondii pcb = mee 3204225 Acrodermatitis; cyclosporine; therapy, 3200148 3200716; etoposide, quality assurance, 3205303;
coCmobllianbeodr attihoenr,a py3;2 0e1v5a5l5ua tion, Intercompany Acromegaly; octreotide; effects, lipid metabolism, ftaotx iceimtuyl, si3o2n0s0 08st2a;b iliftayt , em3u2l0s6i3o0n9s;- pafraet netmeurlasli ons,
condoms; use, consultation, pharmacists, 3200545 3202498 nutrition, 3206301; fluconazole-paclitaxel
didanosine; interactions, pentamidine, toxicity, Acronychia eS flavonols; isolation, cytotoxic incompatibilities, 3200719; furosemide-mannitol
pancreatitis, 3202414 effects, 3204633 incompatibilities, 3205556; granisetron,
drug abuse; Brazil, incidence, prevention, Acrylics 3204934; granisetron incompatibilities, 3204347;
3200876; HIV infections, incidence, prevention, polymers; dipyridamole release, coevaporates, heparin-isosorbide incompatibilities, 3206299;
France, 3200878; incidence, Yugoslavia, 3200680 hospital pharmacy services, 3204148;
3200875; injections, outcomes, 3200855; needle resins; synthesis, physical parameters, 3200234 incompatibilities, 3206290; IV, globulin immune
exchange programs, 3204731, 3204742; ActHib, see Haemophilus b polysaccharide incompatibilities, 3202486; IV, nurses, hospitals,
overview, 3200497 conjugate vaccines Sweden, 3200045; lidocaine-nafcillin
1098 International Pharmaceutical Abstracts
Subject Index Administration
incompatibilities, 3204345; lorazepam, 3204935; pharmaceutical industry attitudes, 3204726; user satellite, patient care, 3201634: OR satellite,
mannitol-sodium bicarbonate incompatibilities, fees, 3200448 3201642; services, 3205333; staff development,
3206288; melphalan, incompatibilities, 3200715; government; England, 3206716 3204824; team, 3205054; technicians staff
microbiological contamination, aseptic filling, guidelines; conflict, 3203432 development, 3204883; therapeutic substitution,
3204129; midazolam, incompatibilities, fentanyl, health care; continuity, 3204991; institutions, histamine H2 antagonists, 3204845; Trendstar,
stability, 3204344; midazolam, incompatibilities, pharmacoeconomics, UK, 3203373; jod 3205011; U.S., UK, 3204971, 3204972; warfarin
morphine, 3200718; milrinone lactate, 3204929; supervision, 3206766; pediatric immunization, monitoring, 3204905
mixing order, 3204930; ofloxacin stability, U.S., 3201311; pharmaceutical education, hospitals; antineoplastic agents, environmental
3206306; ondansetron stability, polypropylene 3200908; resources, costly therapeutic advances, toxicity, 3201499; biopharmaceuticals, task
syringes, 3201841; paclitaxel incompatibilities, 3203987 force, 3201641; IV injections, wastage,
3201293; paclitaxel, vehicles, incompatibilities, health care reform; politics, 3205244 monitoring, 3201530; IV programs, proposals,
administration sets, 3201048; parenteral health maintenance organizations; cimetidine 3203509; medical records, adverse reactions
nutrition, barium contamination, 3200027; utilization, 3204904; costs, 3206813; patient reports, 3203502; patient care, pharmacists role,
parenteral nutrition, stability, 3205481; propofol, consultation, 3204866; pharmacists clinical 3201633; patient care, U.S., 3202247;
incompatibilities, parenteral nutrition, 3202483; rounds, 3204878; pharmacy services, asthma pharmaceutical care, 3204832;
quality control, 3204683; teniposide therapy, 3204871; pharmacy services, emergency pharmacoeconomics, 3206787; pharmacy
incompatibilities, 3203120; theophylline prescribing, 3205010; self care kits, 3204902; practice guidelines, 3202921; proactive
incompatibilities, 3203695; vancomycin, sexually transmitted diseases protocols, 3204877 formularies system, 3202922; protocols,
incompatibilities, 3204932; vehicles, home health care; hospitals, 3200046; infusions, 3204825; quality improvement, JCAHO
incompatibilities, administration sets, 3200238 mergers, 3204065 guidelines, 3200054; vancomycin, utilization
Ademetionine hospital pharmacy, 3204879; adverse reactions evaluation, 3201201
osteoarthritis; magnetic resonance imaging, reporting programs, 3204859; adverse reactions industry; computer programs, groupware,
3204280 reports, 3204818; after hours, clinical pharmacy, 3 ; cosmetics, quality control, 3202898;
pancreatitis; alone and with beta carotene and 3200585; allergies monitoring, 3204847; innovation, power, 3204031
selenium, 3201694 antibiotics utilization, 3204903; anti-infective industry, pharmaceutical; global regulatory
spherocytosis; hereditary, therapy, 3206120 agents costs, 3204965; antilipemic agents, strategy, 3203342; GMP training programs,
Adenocarcinoma; contraceptives, oral; toxicity, 3204956; antineoplastic agents decontamination, 3204107; information technology role, 3204094;
cervix, 3203541 3204797; aprotinin, 3204822; automation, managed care impact, 3204745; Manufacturing
Adenosine 3204804; automation, drug distribution systems, Execution Systems, 3206837; new dosage form
tachycardia; fetal, transplacental therapy, 3205440; 3204892; breast neoplasms therapy, 3204891; development, 3203632; new drug pricing,
labor, 3206091 cardiopulmonary resuscitation, 3204846; clean 3206792; pharmacology research, 3206773;
toxicity; dermatological reactions, 3203545 rooms, 3204801; clinical manuals, 3205002; product development, 3200002; relationship,
Adenosine receptor antagonists clinical pharmacy services, 3200035; clinical pharmacists, 3201516; role, health care reform,
1-benzyl-4-aminosubstituted- | ,2,3-triazole[4,5-d]- services, 3205823; clinical services, 3202763; strategic planning, preclinical
pyridazines; synthesis, effects, 3204523 anticoagulants, 3204826; clinical services, job resources, 3200869; support, national accounts,
2-N-butyl-9-benzyl-8-azaadenines; effects, satisfaction, 3204889; clinical services, pain marketing, 3201562
synthesis, 3204549 therapy, 3204876; clinical services, patient care, information; technology, management, 3200553
2-phenyl-9-benzyl-8-azaadenines; effects, 3204827; colony stimulating factors, Joint Commission on Accreditation of Healthcare
synthesis, 3204550 reimbursement, 3204901; communication, laws, Organizations; standards, development, 3205042
1,2-3-miazolel4,5-dipysidazines, effects, synthesis, 3204840; computer documentation, 3204997, leadership; adverse drug reactions, ethics,
3204542 3205000; computer interfaces, 3204789; 3203967; pharmacy, India, 3205921; pharmacy
S-Ad Imethionine, see Ademetionine computers, 3205005; computers, patient and students, 3200928; 1995 priorities, 3204138
S-Adenosyl-L-methionine, see Ademetionine drug information, 3205290; continuing education managed care systems; selection, 3206815
Adbhioelsoigoicna l, see Bioadhesion pirmopgrroavmesm,e nt3,2 043927084;8 65co;n tcionsutosu sr edquucatliiotny, mNaeteitoinnagls ; Hewaolrtkhi ngSe rpvairctei;e s,d rruegp orctoss,t s, 3230250808478 9
glyburide; excipients, direct compression, 3204964; critical pathways, 3204836, 3204853, nurse practitioners; prescribing, 3205801
3202905 3204873; decentralized, 3205326; dosage pain; overview, 3204037
Adhesives; biological, see Bioadhesives adjustment, 3204869; downsizing, 3204141; personnel; safety, 3205831
Adciignaareztotlesa,m phmaersmyalcaotkei;n etiintcesr,a ct3i2on0s3;0 5s5m oking dtrreungd s,d is3t2r0ib2u7t5i4o;n seycsotneommsi,c s,3 20U4.7S9.9, ; 32e0c4o0n0o7m;i c pe3r2s0on2n8e4l5, pharmacy; hiring practices, survey,
Aditoprim; comparison, trimethoprim; emergency drug list, 3200038; fentanyl! analysis, pharmaceutical care; clinical pharmacists,
pharmacokinetics, buffalo, 3200369 theft, 3204945; financial management, employee 3204833; continuity, 3204983; pharmacy
Adjuvants, see Excipients involvement, 3200055; food-drug interactions, educators, 3204835
Administration 3204838; formularies, clinical services, survey, pharmacists; health care reform, 3205914
American Society of Health-System Pharmacists; 3200587; formularies, pharmacoeconomics, pharmacists, community; role, 3204083; time
protocols, 3205991 3200480; geriatric assessment team, 3204809; management, 3206834
chain stores; pharmacy benefit management geriatrics, 3204830; health care reform, pharmacists consultant; billing, case study,
company, 3204075 3202265; integrated health care, 3204854; 33220004504579; continuous quality improvement,
cclliinniiccaall psthuadrimeasc;i sbtlso;o d H.s apmyplloersi, clsitnoircasg,e ,3 2s0h2i8p1me6n t, 3in2t0r4a8v4e4n;o usJ CaAccHeOss isnysspteecmtsi,o ns3,2 0342802530;4 7;i nvJenCtAorHyO, ph3a2r0m3a5c2is7t;s , dohwonsspiitzailn;g ,c osmumruvenyi,c a3t2i0o2n2 51s;tr at1e9gi9e5s ,
3203190; coordinating center project manager, standards, drug sample dispensing, 3203328; job outlook, 3205045
responsibilities, 3201584; investigational performance agreements, 3204819; job pharmacy; benefits management, 3206823;
antineoplastic agents, research protocols, performance review, 3204842, 3204858, continuous quality improvement, 3202820;
3201076 3204894; loss of senior positions, England, generic drugs, group purchasing, 3203396;
decision making; clinical pharmacists, 3205324 3200056; manpower, 3202257; manpower, cost generic drugs, purchasing criteria, 3203408;
documentation; electronic, archiving requirements, control, 3200586; manpower reduction, health care reform, 3205242; hiring personnel,
3204091 3204899; medical errors reduction, 3202916; guidelines, 3201604; home health care options,
drug information; professional inquiries, medication errors, 3204959; medication errors, 3204061; journals, survey, 3201043; liability,
pharmaceutical industry, 3203463 relation, work load, 3200034; risk management, 3202718; ownership,
drug information centers; computers, 3205006; methylprednisolone protocol implementation, Australia, 3203946; practice, 3205913;
hospital pharmacy, telephone, 3201034 3202362; missing doses, 3204812; night shift, providers, managed care systems, 3203507;
drug utilization; outcomes — 3204009 3204861; operations review, methodology, taxes, laws, Australia, 3203945; U.S. Air Force,
drugs, see Drug administra 3203928; outcomes research, 3204975; survey, 3202248
drugs, over-the-counter; Rx n>s OTC, 3205202 parenteral nutrition, 3204974; parenteral pharmacy and therapeutics committee; decision
education; nursing, 3205254 nutrition contracts, 3204864, 3204890; patient making, formularies, 3202256
education, pharmaceutical, 3205263; AACP Task care, 3201635, 3205995; patient consultation pharmacy, community; Business Corporation Act,
Force recommendations, 3203424; clerkships, services, 3200042; pharmaceutical care, 3201507; chain stores, technology, 3202869;
geriatrics, 3203430; clerkships, nontraditional 3204821, 3204834, 3204862, 3204874; home health care, 3202840; managed care
PharmD, 3204051; community pharmacy pharmaceutical care implementation, 3202269; systems, 3202859; management, overview,
management, 3200988; curriculum, 3205259; pharmaceutical care, manpower, 3201072; 3201030; management, pharmacists, 3200540;
curriculum, clinical pharmacology, 3204047; pharmacists, night shifts, 3200039; pharmacy OTC sales, 3202782; pharmaceutical care,
curriculum, quality assurance, 3203935; services, 3205056; phenytoin protocols, 3202848; pharmaceutical care implementation,
curriculum, U.S. health care policy, 3204046; 3204910; physician prescribing, quality 3202817; service, consumers perceptions,
drug information, U.S., 3203427; educators assurance, 3202258; physicians prescribing, 3203444; theft prevention, 3202192, 3202195;
scholarship, 3203434; entrepreneurship, 3204863; purchasing, 3205344, 3206740; Pyxis total quality management, 3206809
3205256; faculty, AACP Task Force implementation, 3205931; quality assurance, pharmacy, institutional; asthma protocols,
recommendations, 3203435; methodology, 3204839; quality assurance, JCAHO standards, 3204825; downsizing, 3205044; drug costs, 1995
3200829; nontraditional, 3205254, 3205258; 3204814, 3204831, 3204896; quality assurance, projections, 3202739; infusion pumps, hospices,
nontraditional PharmD, 3204053; nontraditional medication carts, 3204860; quality assurance, 3204852; long term care, financial analysis,
PharmD, hospital pharmacists, 3200880; team, 3204837; quality improvement, failure 3203991; medical error prevention, new
pharmacoeconomics, 3205251, 3205257 mode and effects analysis, 3200412; personnel, 3202918
Food and Drug Administration; CDER, changes, reengineering hospitals, 3204815, 3204886, pharmacy services; anti-infective agent
3204725; computer assisted NDAs, 3203357; 3204887, 3204895: resolving conflicts, 3204137; substitution, 3204811; community, 3205288;
International Pharmaceutical Abstracts
Administration Subject Index
costs, 3204813; drug administration routes Adrenolytic agents, see Sympatholytic agents albuterol, combination, isopropylatropine; liquid
conversion, 3204856, 3204969; drug histories, Adriamycin chromatography, 3203232
3204849; fee for service, 3204980; formularies, see Doxorubicin albuterol sulfate; performance, temperature,
3204882; hospitals, 3204851; impact, 3204843; see Doxorubicin hydrochloride moisture effects, 3201613
patient controlled analgesia, 3204870; pediatrics, Adrucil, see Fluorouracil alcohols, cetyl, combination, colfosceril palmitate,
3204841; physicians prescribing, 3204829; Adsorbents tyloxapol; adult respiratory distress syndrome
satellite, 3204850; specialized devices, 3204893; charcoal activated; poisoning, Tasmania, 3201546; therapy, 3201125
technicians job description, 3204897 sertraline overdose, 3206041; toxicity, GI anti-inflammatory agents; asthma therapy, patient
policies and procedures; antibiotic resistance, complications, aspiration, 3200607 compliance, 3203008
3205156; conflict of interest, 3204958 smecta; interactions, cimetidine, ranitidine, budesonide; allergic rhinitis therapy, overview,
cosmetics toxicity, industry testing, 3202945; 3202690 3201879; therapy, overview, 3203143
drug administration, pediatrics, 3202531; drug Adsorption carbon dioxide; density, pressure effects,
information centers, 3202209; economics, barbiturates; aluminum, effects, octoxynol 9, microparticle properties, 3201621
3205845; hospital pharmacy, roentgenographic 3203104 cinalukast; LC, stability, 3201429
agents, 3201033; hospitals, drug manuals, beta blockers; bucrylate nanoparticles, cosmetics; history, 3202728
3200582; hospitals, drug samples, 3202246; dielectricity, 3203662 decongestants; allergic rhinitis, OTCs, 3204489
hospitals, IV injections rate, 3200583; hospitals, cellulose ethers; interfacial tension, 3204336 deoxyribonuclease; stability, nebulizers, 3203691
IV tubing change, 3201071; institutional chromonar; interactions, 3206179 detirelix acetate; pharmacokinetics, pulmonary
pharmacy, 3204898; iV globulin immune, home dextrans; poly(butyl cyanoacrylate) nanoparticles, absorption, 3203619; pulmonary absorption,
therapy, 3203718; latex allergies, 3204857; 3641 dogs, 3203620
mmeeadsilceasl sicmhmouonlisz,a tPiPonD, tecsotlsl, egoesn, e3 2031251095;8 51; drluigpso;p hialcitciivtya,t eda lcbhuamricno ale,f fe3c2ts0,4 12352;0 31m0e9m branes, dideettheyclthieonx,y l HpEhPtAha laftielt,e rsc odmepfaercitss,o n,3 20E0m0e2r2y 3004;
new medical technologies, 3204 enoxolone, comparison, glycyrrhizic acid; dornase alfa; cystic fibrosis therapy, 3203771
p3h20a3r4m0a7c;o ecporensocmriicbisn,g , nderoupgl asadmmsi niostlratlio n, fialngtriahsteipma;t otionxciocm paetfifbeicltist,i ersa,t s, si3l2ic0o5n6e0 8r ubber dErmuegr ya dm3i0n0i4s,t ractoimopna;r isporont,o codlise,t hy3l2h0e4x2y7l 7 phthalate;
hospitals, 3200590; standard vs experimental catheters, 3202481 detection, HEPA filter defects, 3200022
therapy, 3204756; venous access devices, gases; effects, dissolution, 3201835 fluconazole; therapy, overview, 3203143
hospitals, 3203513 glass, comparison, polypropylene, polyvinyl inhalers; devices, patient information, 3200024;
strategic planning; pharmaceutical industry, chloride; drugs, containers, 3202485 metered dose, 3205932
Suprhvaerimlalcanyc,e 3a2n0d3 4C4o6n trol of Pathogens of glaynctyirhrehpiaztioct oaxciicd , efcfoemcptsa,r israotns,, 3e2n0o5x6o0l8o ne; le3u2p0ro4l3i0d2e acetate; absorption, suspensions, dogs,
mEopniidteomriionlgo,g ic3 20I1m0p3o2r tance; antibiotics resistance iinnssuulliinn;o traodpmiinn;i stfrialtteiros,n 3s2et0s5,9 7n6e onates, 3204351 man2u0f5a9c3t8ur ing; production growth, UK, Europe,
tests, laboratory; electronic data transfer, 3203461 pilocarpine hydrochloride; aluminum, octoxynol methyl ether; overview, 3202224
Vaccines for Children; pediatric immunizations, 9, 3203104 morphine sulfate; dyspnea therapy, nebulizers,
U.S., 3200845 poloxamer; polyalkylcyanoacrylate nanocapsules, 3203135
Adamdiminniissttrraattiioonn sseettss , see Surgical supplies; poly0m5e5rs3;5 atomic force microscopy, 3203828 naofvaerrevliine w,a ce3ta2t0e2;5 9i2n tranasal endometriosis,
Administrators polypropylene, comparison, glass, polyvinyl particle size distribution; metered dose inhalers,
Food and Drug Administration; attitudes, chloride; drugs, containers, 3202485 chamber design, 3203477
inspections, Europe, 3204698 polystyrene; isotherms, rat intestinal mucosa, pentamidine; P. carinii pneumonia, 3205425
hospital pharmacy; role, expansion, 3203510; 3203656; rat intestinal mucosa, 3203655 pharmacokinetics; asthma therapy, review,
strategic planning, 3204834; survey, 3205996 polyvinyl chloride, comparison, glass, 206625
ph3a2r0m3a4c4y3; satisfaction, wholesalers, survey, prpootleyinpsr;o pyalleunmei;n udmr ugosx,i dceo-nwtaatienrer s,in te3r2f0ac2e4,8 5 psaolwmdeetresr;o l drxyi nadfiosapteer;s iodnrsy, p3o2w0d0e5r6 6 inhalers,
pharmacy services; clinical coordinators, 3203521; 3202479 06
communication skills, 3203517; leadership skills, pyridoxine hydrochloride; charcoal vs P. tuber- valves; formulation changes, 3202231
3203518 regium, in vitro, 3200229 Afghanistan; drug abuse; HIV infections,
AAddnmeixxittuirse s, see Additives; injections sstmeercotiad;s ; caimleutmiidniunem,, reafnfietcitdsi,n e,o ct3o2x0y2n6ol9 0 9, 3203104 Afilnactiodxenicne , B 3,2; 0c0o4n9t8a mination; pepper powder,
ctohenrtarpayc,e pt3i2v0es0,2 76o ral; review, 3204419 su3c2c0i4n3yl5c3h oline chloride; plastics, injections, Af32r0a5m97o3m um aulacocarpos; diterpenes; isolation,
Adolescents Adulteration; Crocus sativus; C. officinalis, T. antimicrobial and cytotoxic effects, 3204636
alcoholism; sociology, genetics, 3205875 erecta, 32! Africa
al3c2oh0o5l8s7,4 ethyl; prevention programs, schools, Adsveee rasles o D3r2u0g0 45R8e,a ct3i2o0n0s5,6 53, 20332503007 75, 3200840, addrvuegrst,i seisnsge;n tidarlu;g se, coentohimcisc,s ,3 20n0ee5d1s1, 3200857
ce3nt2r0a3l5 7n1e rvous system stimulants; utilization, 33220012439613,, 33220012661925,, 33220022063939,, 33220022275027,, 33220022289182,, plmaendtsi;c inmaeld,i cifnoallk, meadnitci-iunlec,e roangteinviicr,a l raetfsf,e ct3s2,0 2131;
contraceptives; therapy, 3204427 33220023937535,, 33220033340167,, 33220033351031,, 33220033352032,, 33220033394697,, 3202132
coinmtprlaacnetpst,i ve3s2,0 0o1r3a2l, comparison, levonorgestrel; 33220044288282,, 33220044289407,, 33220044785577,, 33220044880589,, 33220044891087,, AAffrtienr, hsoeuer sO xsyemrevticaez,o lsiene e Hohuyrdsr;o chafltoerr idheou rs
dderpurge sasbiuosne,; 3A2l0a2sk0a0,6 survey, 3204762; and drug 33220056209641, 3205360, 3205800, 3205808, 3205926, AGs-er3v3i1ce; injections; lyophilization, stability,
trafficking, African Americans, 3203380; 3201064
cannabis, prediction, models, 3205784; parents, Adrveeacrtsieo nsd rug reactions, see Drugs, adverse AG-85
peer influences, 3203383; prevention, 3206736; chromatography, a and impurities, topical
relation, childhood abuse of parents, 3205867; Adavlecorhtoilssi,n ge thyl; effects, auto accidents, 3205222 preparations, 320323
self esteem, 3206803; self reports, arrestees, cards; drugs, accuracy, references, 3206839 liposomes; mice, 3206182
3204692; sociodemographic, 3206799; survey, cosmetics; natyral product formulations, 3203094; globulin immune; hepatitis
dr1u9g6 9t-r1a9f9fi4c,k inEgn;g lAafnrdi,c an3 20A3m9e7r5i;c anUs.,S ., 3230230367794,1 televisio7n , 3205836; vs drugs, regulations, €Ag art;r anasnmdi ssciaornb,o xy3m2e0t3h3y2l4c ellulose sodium;
3203382, 3203385; and drug abuse, news media, drugs; ethics, Africa, 3200511; MIMS, ethics, ibuprofen release, suppositories, 3203667
3203451; laws, cases, African Americans, 3203449; regulations, Great Britain, 3205820; Agarose; gels; drug diffusion, 3201279
3203337 regulations, Turkey, 3204710; vs cosmetics, Age
levonorgestrel; contraceptives, implants, 3200252 regulations, 3200447 adolescents; alcoholism, 3205875; central nervous
levonorgestrel, comparison, contraceptives, oral; drugs, over-the-counter; young vs geriatrics system stimulants, utilization, 3203571; drug
implants, 3200132 consumers, influences, 3203456 abuse, 3206799; drug abuse, Alaska, survey,
smoking; incidence, 3206750; prevention, industry, pharmaceutical; Vogeler Co., 3203961 3204762; levonorgestrel implants vs oral
3206746 pharmacy, community; market place, 3206760 contraceptives, 3200132
Adozelesin; neoplasms; therapy, side effects, prescription drugs; direct to consumer, 3203418; consumers; attitudes, OTC drug information,
3202979 quality of life, 3204962 3203456; attitudes, OTC drugs, self-medication,
Adrenal gland hyperfunction; therapy; Cushing's smoking; research, 3206746 3205882; benzodiazepine use, community,
syndrome, 3205568 tobacco; industry, 3206750 survey, 3203019; OTC ibuprofen use, 3201714
Adrenal gland hypofunction; therapy, 3206403 Advisory Committee on Immunization Practices, desflurane; effects, pharmacokinetics, 3201439
Adrenal hyperplasia; therapy, 3206403 see United States Public Health Service; effects; folic acid, 3206636; toxicokinetics, target
Adrenaline, see Epinephrine Advisory Committee on Immunization Practices sites, 3201446
Adrenergic agents, see Sympathomimetic agents Aerosil, see Silicon dioxide colloidal externships; preceptor/student evaluations,
Adrenergic blocking agents, see Sympatholytic Aerosil 200, see Silicon dioxide colloidal 3200515
agents Aerosols geriatrics; effects, drug metabolism, 3202672;
Adrenocortical steroids, see Steroids, cortico- albuterol; bronchiolitis therapy, infants, 3203011; gastrointestinal effects, drug therapy, 3201856;
Adrenocorticotropic hormone, see Corticotropin cardiac, electrolyte effects, 3206367; particle pneumonia, outpatient therapy, 3202400;
Adrenoleukodystrophy; erucic acid, combination, size, asthma therapy, 3204317; performance, predictors, driving cessation, 3202189;
oleic acid; therapy, 3202582 temperature, moisture effects, 3201613 predictors, traffic accidents, 3202188; response,
1100 International Pharmaceutical Abstracts
Subject Index Alcoholism
hypotensive agents, 3203181; warfarin toxicity, effects; adverse drug reactions, 3202936 release; hydrogels, 3206233; microspheres,
3205387; = senile dementia hormones; effects, geriatrics, 3201947 3206230
therapy, 3203551 Aglycones; lochroma gesnerioides; isolation, Albumin bovine derivatives; complexes;
men; thrombolytic agent utilization, 3200482 identification, 3203284 eS glycol, 3206209
neonates; gestational, phenobarbital, phenytoin gran Albumin human
binding, 3202666 clozapine; toxicity, 3201109; toxicity, binding; ketoprofen, 3206614; tolmetin,
patients; adult immunization, 3204368; adverse schizophrenia therapy, 3204208 zomepirac, 3202122
drug reactions, hospitals, 3202280; amoxicillin, colony stimulating factor; paclitaxel toxicity, comparison, albumin bovine; carprofen binding,
combination, clavulanate potassium, toxicity, 3206132; therapy, infections, 3203588 3202559
3202309; antineoplastics, breast neoplasms, colony stimulating factor 2; therapy, mycoses, microcapsules; amino group, 3200681
3203723; attention deficit disorder therapy, 3206454 microspheres; mitomycin, release, 3201289
3204399; CD4+ T-lymphocytes, 3204366; drugs; toxicity, 3202331 nanospheres; preparation, pH coacervation,
cefpodoxime proxetil pharmacokinetics, phenytoin and primidone; toxicity, death, 3201088 3200030
3202651; cerebrovascular disorders = rime primidone and phenytoin; toxicity, death, 3201088 toxicity; dilutions, 3204155
3201752; cystic fibrosis, adults, 3200774 re;6 -O-(carbox ymethy])chitin; Albumin inated; complexes; vidarabine,
cytarabine therapy, myeloid leukemia, 3200633; applications, 3203206 overview, 3204435
deferoxamine therapy, beta-thalassemia, Agrobacterium radiobacter; metabolism; and Albuterol
p3o2l0y2p4s0,9 ;3 2d0i5f4l0u4o;r omefeftehcytls,o rnsietxhuailn e dycsofluonncitci on, AIstDaSb,il itsye,e pAarceqnutierraeld siolmumtuinonosd eeffifcecites,n cy3 20s3y8n9d6 rome aerosols; particle size, asthma therapy, 3204317;
3200614; effects, tirilazad pharmacokinetics, AIDS dementia complex p3e2r0f1o6r1m3a nce, temperature, moisture effects,
3202661; epirubicin effects, pharmacokinetics, didanosine; prophylaxis, 3202364
3200788; ferrous sulfate therapy, 3206160; zidovudine; therapy, 3205106 asptrhomgar;e sscioonnt,i nu3o2u0s1 13v3s demand therapy, disease
hepatitis B immunization, infants, 3200255; AIDS-related complex; GLQ-223; toxicity, bronchiolitis; therapy, infants, 3203011
home parenteral nutrition, septicemia, 3204175; pharmacokinetics, 3202980 chromatography, liquid; decomposition products,
hypotensive agents, therapy, review, 3203560; AIDS-related opportunistic infections 3206576
ibuprofen lozenges, 3203075; ifosfamide effects, clotrimazole; prophylaxis, 3205424 combination, fenoterol, ipratropium bromide,
pharmacokinetics, 3200790; immunization, U.S., fluconazole; prophylaxis, 3205424 terbutaline; LC, nebulizers, 3203856
protocols, 3201308; insulin self-administration, prophylaxis, 3205570
3201743; lipoprotein metabolism, 3206488; Air cocmhbrionmaattioognr,a phisyo,p ro3p2y0l3a2tr3o2p ine; liquid
magnesium blood levels, 3205712; midazolam cellulose microcrystalline; pressure, spherical comparison, procaterol; bronchodilating,
dosage, endoscopy, 3200652; migraine, granules, effects, 3201836 cardiovascular effects, 3205619
epidemiology, economics, 3201522; moricizine, contamination; microbiological, IV injections, comparison, terbutaline sulfate; nebulizers,
arrhythmia therapy, 3202649; nisoldipine, aseptic filling, 3204129 rational therapy, 3206489
pharmacokinetics, 3202097; phenytcin flow; clean rooms, computer programs, 3203304; comparison, theophylline; asthma therapy,
population pharmacokinetics, 3203895; isolator evaluation, computer programs, models, 3206149
potassium supplements, toxicity, hyperkalemia, 3203447 concomitant therapy, 3202966
3200618; prescription investigation, community manufacturing; requirements, HVAC, 3202227 dosage schedules; surgery, costs, 3201758
pharmacy, 3201600; psychotherapeutic agents pressure; nebulizers, effects, stability, 3201839 effects; cardiac, electrolytes, 3206367
uitniflliuzeantzioan , imDmeunnmiazrakt,i on3,2 030260511;7 32s;e letcetrioodni,l ine pteusrtisf;i ccalteiaonn ; rcooommsp,r esvsaeldid,a tiporno,c es3s2e0s1, 62322 05977 in3h2al0e3r4s;7 6 metered dose, content uniformity,
toxicity, 3202804; valproic acid, review, Airway obstruction; beta blockers; therapy, Albuterol sulfate
3202007; zonisamide pharmacokinetics, 3204624 mechanism of action, 3203697 aerosols; performance, temperature, moisture
pediatrics; chloral hydrate sedation, 3203594; Ajuga chamaepitys; constituents; contents, effects, 3201613
cocaine, neurologic toxicity, 3202319; effects, identification, 3200827 equivalency, generic; sustained-action, 3206180
theophylline excretion, 3200792; felbamate kathisia inhalers; metered dose, chamber design, 3203477
therapy, 3206104; influenza vaccines, antigenic drugs; toxicity, review, 3206464 particles; spray drying, 3205964
drift, 3201127; measles vaccines, fluoxetine hydrochloride; toxicity, 3202321 release; albumin bovine microspheres, 3200696;
immunogenicity, 3203015; phenytoin effects, sertraline; toxicity, 3204191 polymer matrices, 3201247
bblloooodd lleevveellss,, edxocsraegtei,o n,3 20342602068;0 4;t hytrhoexoipnhey,l line ALt-ra0n3q1ui5l2i,z ersse;e tAoxLi-ci3t1y5, 2 therapy, review, 3204482 suppositories; bases, gels, release,
cognitive, motor effects, 3205451; vancomycin Alcpahlairgmeanceosk;i nmeettiacbso,l i3sm2;0 02a0n5d stability, parenteral
dosage, 320166 solution effects, 3203896
pharmacists; continuing education, England, AL-3152; comparison, AL-3802, AL-3803; Alclometasone dipropionate; comparison,
ph3a2r0m4a0c4i5st;s , Socuotmhm uAnfiritcya;, diinsftlruiebnuctei,o n,O T3C2 00863 p3h2a0r0m3a7c8o kinetics, pharmacodynamics, rats, tperdiiaamtcriincso,l on3e2 00ac6e6t8o nide; atopic dermatitis,
antitussive preference, survey, 3203316 AL-3802; comparison, AL-3152, AL-3803; Alcohol deterrents
physicians; protocol compliance, 3205470 pharmacokinetics, pharmacodynamics, rats,
students; AIDS attitudes, 3204023; pharmacy, 3200378 disulfiram; and clozapine, alcoholism,
woa3mc2ea0dn3e3;m8 i6c;at tipbtreuerdaefssot,r mnaiennjocepecl,ta asb3lm2es 0 4cr0oi3nstk2,r ac3e2p0t5i3v9e1s;, ALp3-h23a0r80m03a37c;8o kicnoemtpiacrsi,s onp,h arAmLa-c3o1d5y2,n amAiLc-s3,8 02ra;t s, Alcssouchphoeilrz voipwshiirtoenhn,di raa 3w2ta0hl2e r5a9pd0ye ,l ir3i2u0m3 596; therapy,
effects, aprotinin pharmacokinetics, Alaska; drug abuse; adolescents, survey, 3204762 therapy; review, 3205565
hysterectomy, 3202113; oral contraceptives Albendazole; potentiometry; determination, tablets, tiapride; therapy, review, 3201944
toxicity, breast neoplasms, 3202303; raw materials, 3201425 Alcoholics Anonymous
thrombolytic agent utilization, 3200482 Ibumin alcoholism; automobile driving, sentences,
Aghee3an2lct0yh2 1c6fa6orr e Hreeaflotrhm ; Ceacroen omPiolcisc,y naenwd dRreusges,a rch aalntodhn eerh aepapyna,dr in3w;2i 0tdh4 o2x1fo6ur ruobsiecmiind e;m icnreopshprhoetrice s,s ytnodxricoimtey, AlpcrCooahglirofalomirssn;mi a ,H is3p2a0n6i7c2 4A mericans, 3201575
Heart Failure Guideline; heart failure therapy, 3202626 adolescents; Alaska, survey, 3204762; Canada,
recommendations, 3201306 carriers; diclofenac release, microspheres, survey, 3204759; models, 3205775
protocols; cancer pain therapy, 3202379; low back 3202475 alcohols, ethyl; binge drinking, U.S. college
pain, 3206074; pain therapy, neoplasms, injections; antihemophilic factor, 3204936 students, 3202171; Lysol spray ingestion,
3203575 microspheres; aminophylline release, kinetics, poisoning, 3201536
Agglomerates 3205147; stibogluconate carrier, targeting, anti-inflammatory agents; nonsteroidal, toxicity,
bucillamine; tableting, properties, 3205975 3200231 overdose, 3203536
chlorpromazine hydrochloride; gel microcapsules, vehicles; amphotericin B toxicity, rats, 3200107 automobile driving; sentences, Alcoholics
3203665 Albumin bovine Anonymous, 3206724
furosemide; homogeneity, dissolution, 3205307 binding; warfarin, triamterene, 3203614 benzodiazepines; alcohol withdrawal therapy,
lactose; compaction, 3205520 comparison, albumin human; carprofen binding, 3203041; therapy, alcohol withdrawal, 3203044
microscopy; video-, _ points, 3203837 3202559 calcium carbimide citrated; and behavior therapy,
talc; granules, 3205518 comparison, casein; microspheres, methotrexate effects, 3201765
Agglomeration; particles; spherical crystallization, release, 3203096 clozapine and disulfiram; schizophrenia therapy,
3204112 comparison, lectins; L. esculentum, intestinal 3203596
Aggregation uptake, 3202646 dependence; bi-axial concept, 3202161; use,
carbonic anhydrase; release, microspheres, diffusion; membranes, electricity, 3201257 frequency vs quantity, 3205786
3206217 effects; dibromosulphthalein sinusoidal efflux, diagnosis; hospitals, methodology, 3206676;
fusidate sodium; freezing point, 3205528 rats, 3203276; drug adsorption, filtration symptoms, 3205776
ganglioside GM1; a-cyclodextrin effects, 3201813 membranes, 3203109; liposome stability, disulfiram; therapy, supervision, 3202590
insulin; cyclodextrins, effects, 3201291 3200245 disulfiram and clozapine; therapy, schizophrenia,
Aggression microspheres; albuterol release, site of action, 3203596
buspirone; therapy, 3201187; therapy, 3200696; PVA, temperature effects, 3201628; effects; depression, 3202801; personnel, 3206762;
Huntington’s disease, 3206134 tetrandrine entrapment, particle size, 3201817 phobic disorders, 3202795; sleep, 3201671
Aging particles; pilocarpine ophthalmic preparations, enteral nutrition; therapy, liver cirrhosis, 3200144
Allium sativum; effects, in vitro, 3204479 3203063 Europe; reports, 3206798
International Pharmaceutical Abstracts
Alcoholism Subject Index
Finland; women vs men, 3201576 trichlorotrifluoroethane; skin peels, degreasing thickness; water content, diffusion, dissolution,
methodology; addiction scales, 3204688; indirect agents, 3206449 effects, 3200688
scales comparison, 3205778 concentration; French patent drugs, 3201827; Alcohols, propyl; sorption; dimethylpolysiloxane,
monitoring; physicians guidelines, 3200488 nitroglycerin sublingual sprays, 3203630 Fourier transform infrared spectrometry, 3203836
mortality; treatment effects, 3206058 concomitant therapy, 3205357, 3206041 Alcohols, stearyl; effects; ibuprofen release, wax
nitric oxide; interactions, 3206162 data collection; consumption, methodology, microspheres, 3203475
patient information; self help, 3205863 3202703 Aldactone, see Spironolactone
pharmacogenetics; Japanese, 3202575; prediction, dependence; bi-axial concept, 3202161; diagnosis Aldesleukin, see Interleukin 2
response, 3200866 criteria, 3205776; diagnosis, methodology, Aldosterone antagonists; hypertension; therapy,
pharmacy services; treatment programs, 3201528 3205781, 3205782; Lysol spray ingestion, review, 3203775
physicians; well-being, 3201563 poisoning, 3201536; pharmacists role, treatment Aldrin; toxicity; mice, 3203797
Russian Federation, 3206739 programs, 3201528; self help information, Alfacalcidol; renal osteodystrophy; prophylaxis,
salicylates; toxicity, overdose, 3203536 3205863; tests, Leeds Dependence 3205402
sociology; vs genetics, 3205875 Questionnaire, 3202157 Alfentanil; interactions; drugs, hepatic enzyme
students; Brazil, survey, 3204763; family history, effects; behavior response, hyperbaric pressure, induction, 3203060
survey, 3201574 rats, 3200831; cromolyn percutaneous Alferon-N, see Interferon alfa-n3
tests; methodology, Leeds Dependence absorption, iontophoresis, 3202437; fibrinolytic Algeria; compliance; medications, pediatrics,
Questionnaire, 3202157 factors, dosage, 3200636; ketoprofen permeation, 3201760
therapy, 3205382; Alcoholics Anonymous, mouse skin, 3200195; pharmacodynamics, Algestone acetophenide; combination, estradiol
Hispanic Americans, 3201575; camp approach, immunosuppression, 3203748 enanthate; pharmacodynamics, pharmacokinetics,
India, 3205879; epidemiology, _ 3205883; elixirs; encapsulation, anti-inflammatory drugs, dosage, 3202570
Aletwcfoopfox3merih2cceoo0tignl0str;s;1ya ; 9m 5ks;sew,o ti ctoishpmoidrellrotioafacgweo-ynana,eln ,ap3 leey2lrts0ahim6seset7r,ao9a tmp7iey 3or,2ns 0,, a 61Fm5eoT uIsR e 32sk0i5n5, 65 hiiiinnndcstcsioteoosomrmmsrapponycaoli;ttu uaiit;onbimn dioeslind;di,ni et gcpiaa,ee3cl sn2e ;d0t 3e1ra2n8eam0cs2di1ee1mna0,i or4n cpi8hhsr ,eet lnraa,ttt eiimoolpnniesv hreirasp ne,tct soe,x,3 i 2cpi0a3t1cy2l6,0i7 t61a7 x3e3l AAllGiggant3iituhn2uecear0chrta2eaecerp0rtsya1’i;,sos0 ne s ce;doc ilolsnpoeroiaemdssegi;;nc asn,gtce hlyel3r ia2npt0gye1,s, 9t } s0c,38 a2;lf0 ca5ilt4ushem4e ,1r ,pao p3sy2i3,t02 i10vo26ev7s1e,52r 3v;i ew,
spectrometry, 3202636 3203536, 3203537; acetaminophen, 03053
isopropyl myristate, lecithin and water; pharmacokinetics, 3200374; drugs, 3205483; Algorithms, see Protocols; algorithms
microemulsions, phase diagrams, 3201819 histamine H2 antagonists, lack, 3202419; Alkaline phosphatase; structure; steady state
poisoning; toxicity, Poland, 3204160 h3i2s0t1a7m7i8n;e nainttraicg onoixsitdse,, p3h2a0r6m1a6c2o;k inreatniitcisd,i ne, blood kinetics, 3206541
soirnpftriaorne;d dsipmeectthryolmpeotrlyy,s il3o2x0an3e8,3 6 Fourier transform levels, 3202418; sulfonylureas, toxicity, 3204286 Alpkoatlaisnsiizuimn g caargbeonntast e; furosemide release, tablets,
Alcohols, benzyl methodology; measurement, consumption, 3202430
ch3r2o0m3a2t3o0g raphy, liquid; topical preparations, CNaenwa daZ,e al3a2n0d2,7 0312;0 2m70e2a;s urmeemaesnutr,e mecnotn,s umption, so3d2i0u5m5 52b;i cairnbcoonmaptaet;i bielfifteictess,, F3C2E0-4232471,0 1 32s0t6ab2i8l8it;y ,
ef3fe2c0t1s;2 96e;r ytlhercoiptohiien timni xseodl utmiiocnesl,l ess,ta bi3l2it0y4,3 3s4t orage, micsounsseu;m pStiiboenr,ia , U.3S2.,0 5838230 2700, 3202705 l3i2m0u5l3u6s2 ;t estths,e rappHy,, 3a2co0n4i1t1e4s; postiastounsi negp,i le3p2t0i4cu1s6,3 ;
Alscoolhvoatless,; bsuutcycli nylsulfathiazole, 3205538 ppaantcireenait iitnifs;o rmcaotriroenl;a ticono,n sudlettaetcitoino,n , ph3y2s0i2c5ia5n4s tthheiroarpiyd,a zilniet hipuomi sotnoixincgi,t y,3 230200046198 5; therapy,
sorption; dimethylpolysiloxane, Fourier transform guidelines, 3200488 urinary tract infections; therapy, 3204433
infrared spectrometry, 3203836 physicians; abuse, well-being, 3201563 Alkaloids
Alcohols, tert-butyl; and water; gentamicin poisonings; antidotes, 3205342 berberine; antimicrobial activity, 3206645
lyophilization, 3204339 purchasing; data collection, methodology, Norway, Citrus aurantium; mice, 3205734
Alccoomhboilnsa,t iocnet,y l colfosceril palmitate, tyloxapol; so3l2ve0n2t7s0; 4 thiazide diuretics, 3203854 Coacncaullgeussi c hierfsfuetcutss;, irastosl,a ti3o2n0, 32a9n2t i-inflammatory,
a3d2u0l1t1 2r5e;s piarnatdo rpyr edniasttarle ssd exsaymnedtrhoamseo net,he ranpeyo,n ates, soirnpftriaorne;d dsipmeectthryolmpeotlryy,s il3o2x0an3e8,3 6 Fourier transform cCorpitniusimn e;a maCb.i lmea;j usi,s olTatLiCo,n, iadnetnitmifailcaartiiaoln , an3d2 01467
3201713; respiratory distress syndrome, stability; temazepam, 3205558 cytotoxic effects, 3205751
npeuolnmaotnesa,r y cohste mobrentehfaigt,e , 32n0e3o9n7at7e;s , to3xi2c0i1ty6,6 4 to3xi2c0i0t0y8; 7;d eaGtlh,, wAuosutnrdias, a3n2d0 60in5j7u;ri ese,p is3t2a0xi2s3,0 6; Dacthulroar aminpnhoexniiac; olp heenffyelcatlsa, ni3n2e0 26in8c0o rporation,
Alcohols, dodecyl insomnia, 3200293; mortality, dosage, 3200596; echimidine; comfrey product determination,
colmapuarroicsaopnr,a m;d odpercoyplr anNol,oNl-,d itmiemtohloyll ampienrcou taacneetoautse, ustee;r aCtaolgiefnoircnitiya,, kmioddneelys , an3o2m0a5l7i7e9s;, c3h2r0o5n3o7t5y pe, Fr3it2i0l1la4r8ia2 species; effects, antitussive, expectorant,
absorption, 3200193 personality, 3202797; Europe, reports, 3206798; 3205749
comparison, dodecyl-N,N-dimethy|-L-alanine; frequency vs quantity, dependence, 3205786; Guatteria foliosa; isolation, trypanocidal effects,
drugs, percutaneous absorption, 3201406 men, Sweden, 3205886; prevention programs, 3204634
Alacbouhsoel;s ,a ddeitchtyilo n scales, methodology, 3204688; ps3at2ru0ed5ne8tns6t,s9 ,; 332R20u05s58s86i77a4;n; rFeresedileasrttaiatoninc,oe n,, c hsit3lu2dd0eh6no7to3sd,9 ; asbosucesiroevl iocogefy , He3i2m0i0a3 92sa licifolia; pharmacology. review,
adolescents, Alaska, survey, 3204762; industry personnel, Norway, 3205860 Lonchocarpus species; isolation, identification,
adolescents, Canada, survey, 3204759; utilization; geriatrics, predictors, driving cessation, 3204667
adolescents, models, 3205775; adolescents, 3202189 ornithine; accumulation, phaseolotoxin effects, D.
parents, peer influences, 3203383; Alcoholics vehicles; effects, diclofenac penetration, 3205491; innoxia, 3203298
Anonymous, Hispanic Americans, 3201575; parenteral injections, pain models, rats, 3200411 oxymatrine; lymphocyte proliferation, 3206417
binge drinking, U.S. college students, 3202171; withdrawal; clomethiazole toxicity, 3204151; Psilocybe samuiensis; isolation, 3204653
depression, 3202801; diagnosis, hospitals, puntarenine; antimicrobial activity, 3206645
Tmaestmhaondioal,o gy3,2 013524066;6 76h;i ghd rsucgh ooovle rsdtousdee,n ts, Alctoohxoilcsit,y , fatthteyr;a pyc,o mb3i2n0a5t5i6o5n , propylene glycol; so3l2a0so2d1i4n7e ; isolation, berries, S. khasianum,
vehicles, piroxicam release, fatty acid effects,
Canada, 3206791; personnel, 3206762; 3201794 synthesis; antifungal effects. in vitro, 3204522;
pharmacogenetics, Japanese, 3202575; phobic Alcohols, isopropyl Chinese medicinal herbs, 3202085
disorders, 3202795; prenatal exposure, fetal absorption; percutaneous, sodium carboxylates, tetrandrine; albumin microspheres, 3201817
growth, 3204168; prevention, 3206736; 196 Tussilago farfara; identification, 3201484
response, alcoholism prediction, 3200866; self combination, chlorhexidine gluconate; Vincetoxicum hirudinaria; isolation, identification,
esteem, 3206803; students, Brazil, survey, comparison, degreasing agents, skin peels, 3203285
3204763; students, family history, survey, 32 06449 Alkeran, see Melphalan
3201574; therapy, meta-analysis, 3206155; Alcohols, methyl B-[(2-Alkoxyethyl)oxy Joxyacetamides; synthesis;
toxicity, mortality, 3206058; toxicity, therapy, and water; solvent effects, models, 3201495 H ,-antihistaminic activity, 3202629
3205382; treatment outcome, day hospital effects; ketoprofen permeation, mouse skin, 1-Alkoxymethyl-4-dimethylaminopyridinium
programs, 3200868; women vs men, Finland, 00195 chlorides; synthesis; antimicrobial effects,
3201576 solvates; 9,19-anthraquinone-2-carboxylic acid, 320652
accidents; decrease, England, 3205222 3203115 Alkoxyphenyl carbamic acids; synthesis;
and (—)-menthol; percutaneous drug absorption, sorption; dimethylpolysiloxane, Fourier transform pharmacology, 3203220
3201225 infrared spectrometry, 3203836 Alkylamines; effects; poly(€-caprolactone)
and metrizamide; compounding, arteriovenous Alcohols, octyl; and water; partition coefficients, decomposition, 3203684
malformations therapy, 3200674 ortho aromatics, 3201283 Alkylating agents, see Antineoplastic agents
and sucrose; microemulsions, phase behavior, Alcohols, pentyl; solvates; succinylsulfathiazole, Alkylation
3202480 3205538 2,7-diazabicyclo [4.1.0] hept-3-enes; synthesis,
and trioctanoin; vehicles, percutaneous drug Alcohols, polyvinyl alkylating effects, 3203827
absorption, 3202120 and povidone; transdermal indomethacin patches, 1,4-dihydropyridines; synthesis, alkylating effects,
automobile driving; sentences, Alcoholics 3200706 3203827
Anonymous, 3206724 concentration; effects, albumin bovine {(N-Alkyl-1,3-dihydro-1-oxoisoindolin-5-yl)oxy]-
comparison, acetone, alcohols, isopropyl, microspheres, 3201628; polyglactin 370 alkanoic acids; effects; chlorine transport,
combination, chlorhexidine gluconate, microspheres, 3206222 astrocyte cultures, 3203179
1102 International Pharmaceutical Abstracts
Subject Index American Association of Colleges of Pharmacy
Alkylpolyglycosides; manufacturing; synthesis, constituents; identification, 3205720 Alzheimer’s disease
3205944 cosmetics; research, 3204119 L-carnitine; therapy, 3202618
4-Alkylpyrazoles; synthesis; liver alcohol therapy; history, research, 3206641 parasympathomimetic agents; new drug
3-d(e2h-yAldkryoigtehniaos-e 6-ibn hibition, 3206535 thyl)-2- All amivudine; adverse reactions, 3205061 padteivenetl o—pment, 32065p2h5a rmacists, caregivers,
thi. structure-- activity minoxidil; therapy, women, 3201881 320377
relationships; ‘in vitro, 3203218 Alovudine; HIV infections; therapy, tacrine; i toxicity, 3200272; blood levels,
1-Alkylthi hyl-4 i pharmacokinetics, overview, 3201679 3205432; therapy, review, 3201942
chlorides; synthesis; antimicrobial effects, Alpha hydroxy acids; skin and mucous membrane tacrine hydrochloride; therapy, overview, 3201941
3206521 preparations; sales, 3205854 therapy, 3203171; overview, 3202046, 3202067,
Allantoin; Aloe vera; constituents, 3201863 d-Alpha-tocopheryl-polyethylene-glyco1l00-0 3205574
Allergies succinate, see Tocophersolan Amantadine
allopurinol; hypersensitivity, 3204152 Alpidem; toxicity; hepatitis, 3200092 basal ganglia diseases; therapy, neuroleptic
amphotericin B; liposomes, adverse reactions, Alpinia galanga; effects; lack, cytotoxicity, toxicity, review, 3204482
3202935 mutagenicity, 3204651 influenza; prophylaxis, geriatrics, review, 3201858
ampicillin; hypersensitivity myocarditis, Alprazolam Parkinson disease; overview, 3205599; therapy,
pediatrics, 3201643 comparison, bretazenil; pharmacologic effects, 3206323
antineoplastic agents; overview, 3206050 abuse potential, 3202345 Amantadine hydrochloride
antivenins; epinephrine premedication, effects, comparison, suriclone; pharmacokinetics, chromatography, gas; plasma, 3203241
3202033 pharmacodynamics, 3202121 influenza; prophylaxis, 3206372
aprotinin, 3204822 crystals; physical properties, 3205142 Amastatin; effects; leucine enkephalin stability,
Asarum sieboldi; constituents, effects, 3205623 panic disorders; therapy, sustained-action, 3201232
carbimazole; adverse reactions, hearing loss, 3204263 Amauroascus niger; zaragozic acids; isolation,
tinnitus, 32! utilization; evaluation, nursing homes, 3201130 enzyme inhibition, 3200396
cefaclor; serum sickness, pediatrics, 3200079 withdrawal; panic disorders, 3206033 Ambergris; perfume; properties, applications,
cefuroxime; nephritis, 3202937 Alprenolol; thermal analysis; enantiomers, 3206215
clavulanic acid, combination, ticarcillin; transdermal transport, models, 3201397 Ambien, see Zolpidem tartrate
desensitization, sinusitis therapy, 3202363 Alteplase AmBisome, see Amphotericin B
cosmetics; students, 3202973 and plasminogen activator inhibitor 1; analysis, Ambrosia maritima; effects; lack, larvicidal,
D&C Red No. 7; contact dermatitis, lipsticks, 3205684 3202135
3201080 comparison, streptokinase; myocardial infarction, Ambroxol hydrochloride; chromatography; UV
dexamethasone; adverse reactions, dermatitis, rational therapy, 3203023; myocardial infarction spectrometry, tablets, 3203254
3202959 therapy, 3202387 Ambulatory care
digoxin; toxicity, blood levels, 3201645 comparison, streptokinase, urokinase; arterial asthma; therapy, 3204871
dobutamine hydrochloride; toxicity, dermal occlusive diseases, 3201186 certification; curriculum, 3200947
cellulitis, 3200071 coronary disease; comparisons, 3205756 clerkships; community pharmacy, drug
drugs; adverse reactions reports, hospital effects; hematologic, immunologic, review, information databases, 3200974; nontraditional
pharmacy, 3203502; causes, overview, 3202279; 3201910 PharmD, 3200912
documentation, 3204808; hepatitis, mechanisms, myocardial infarction; dosage, preparation, compliance; outpatients, 3204995
overview, 3202281; pharmacists interventions, 3203813; therapy, 3206031 control, quality; patient compliance, electronic
3201637; pharmacy services, 3204847; rashes, Alternative medi monitoring systems, 3201631
overview, 3201647 acupuncture; review, 3206790 drug interactions; incidence, geriatrics, 3206178
drugs, over-the-counter; community pharmacists, aromatherapy; skin, photoaging, 3206458 education, pharmaceutical; clerkships, geriatrics,
recommendations, 3202827 dermatitis; atopic, 3206318 3203430
erythromycin; dermatosis, eosinophilic, 3200076 diarrhea; homeopathy, pediatrics, 3201717 ferrous sulfate; rational therapy, geriatrics,
food; pediatrics, diagnosis, 3200775 education, pharmaceutical; curriculum, 3200941 3206160
ginseng; guinea pigs, 3206022 geriatrics; nursing homes, 3201579 geriatrics; multidisciplinary assessment team,
histamine H2 antagonists; effects, 3201962 herbs; liver toxicity, 3205066 3206011
homeopathy, 3202541 homeopathy; community pharmacy, 3200533, health care reform; pharmaceutical care, coalition,
isoniazid; hepatitis, 3202282 3202174; marketing, 3206757 3201515
ketoprofen; adverse reactions, topical Larrea tridentata; toxicity, 3205065 hospital pharmacy; medication errors, 3204959;
preparations, 3200066 neoplasms; therapy, Australia, pediatrics, unclaimed prescriptions, 3205039
latex; adverse reactions, 3203534, 3204857; 3202589; therapy, pediatrics, 3202588 patient information; consultation, 3200946
anaphylaxis, 3206013; anaphylaxis, surgery, overview, 3204738 pharmacy services; clinics, 3201014; pharmacists
3200077 pediatrics; homeopathy, respiratory tract infections role, 3204816
measles vaccines; tests, pediatrics, 3200072 therapy, 3203989 smoking; cessation, 3204993
minocycline, 3206020 plants; medicine show, 3204030 vitamins; supplementation, 3201010
on3d2a0n2s2et7r6o n; adverse reactions, anaphylaxis, AlUtniittuedde Sstiactkens;e sst;r ensdsu,m at3r2i0p2ta7n8;8 headache therapy, AAmm3de2ib0ni2oc5ci3id2le lsi n; models; pharmacodynamics,
paclitaxel; adverse reactions, IV infusions, 3203567 chlorhexidine; acanthamoeba keratitis, combined
1886 Alumina, see Aluminum oxide therapy, 320377
pparteisecnrti pteidounc atdiroung;s ; phmaarilm acoirsdtesr,, p3h2a0r1m8a7c4is ts AAlluummiinnai-uCm,, sseeee AAlluummiinnuumm sodium oxide netohmeryacpiyn,; 32a0c3a7n7t0ha moeba keratitis, combined
stienrtoiedrsv,e ntcioorntsi,c o-3; 20o0v8e5rv0i ew, 3201646 AAlluummiinniiuumm thryidsrtoexairadtee,, sseeee AAlluummiinnuumm hsytedarroaxtied e pokleryahtietxias,m etchoymlbeinnee d bitghuearnapiyd,e ; 32a0c3a7n7t0h amoeba
sucralfate; adverse reactions, anaphylaxis, Aluminum
00080 absorption; sucralfate tablets, suspensions, prtohpearampiyd,i ne3;2 03a7c7a0n thamoeba keratitis, combined
sunscreen agents; dermatitis, 3200620 3201800 Amenorrhea
terfenadine; substance P, vasoactive intestinal combination, magnesium; antacids, toxicity,
polypeptide, 3201181 water-electrolyte imbalance, 3202946 brhoympoecrrpirpotliancet,i necmoimap,a ritshoenr,ap y,c ab3e2r0g0ol1i1n1e ;
therapy, 3204439 interactions; cimetidine, ranitidine, 3202690
Allicin; Allium sativum; antioxidant effects, in toxicity; encephalopathy, seizures, cements, cahbyepregroplrionle,a ctcionmepmairai,s otnh,e rabpryo,m o3cr2i0p0t1i1n1e ;
vitro, 3206413 3205076 American Academy of Dermatology; education;
Allium sativum Aluminum chloride; suspensions; allopurinol, consumers, skin neoplasms, 3201907
effects; anti-aging, in vitro, 3204479; anti- stability, 3200236 American Academy of Family Physicians;
arthythmic, dogs, in vitro, 3203800; antioxidant, Aluminum hydroxide hepatitis B vaccines; universal immunization,
in vitro, 32! 13 combination, dicyclomine hydrochloride, physician attitudes, 3203768
Allopurinol magnesium oxide; interactions, nifedipine, American Academy of Pediatrics
allergies; hypersensitivity, 3204152 3204328 camphor; toxicity, recommendations, 3201653
gout; therapy, 3206336 combination, magnesium hydroxide; interactions, guidelines; pertussis vaccination, Australia,
soiubility; 2- , 4-methylbenzoic acid, effects, nifedipine, 3204328; interactions, ondansetron, 32020
3205551 3202425; sensory analysis, methodology, hepatitis B vaccines; universal immunization,
suspensions; stabilizers, flocculating agents, 3203322 physician attitudes, 3203768
3200236 toxicity; motor impairment, mice, 3201112 inhalers; exercise-induced asthma, protocols,
therapy; cervical swelling, 3206143 Aluminum oxide 3201693
Almagate; comparison, antacids; effects, gastric and water; adsorption, proteins, 3202479 protocols; hepatitis B immunization, pediatrics,
residence time, 3200693 combination, magnesium hydroxide; interactions, 3200255; immunization, 3201695; measles
+-Almeine; reactions; +-araliopsine, synthesis, pefloxacin, pharmacokinetics, 3203608 vaccines, immunization, globulin immune
3200311 reactions; inorganic supports, 3200328 therapy, 3202398
Aloe species; chromatography; leaf exudates, Aluminum sodium oxide; adsorption; drugs, American Association of Colleges of Pha
storage, 3206640 effects, octoxynol 9, 3203104 Council of Faculties; strategic planning, 3205255
Aloe vera Aluminum stearate; lubricants; effects, terbutaline health care reform, 3205261, 3205263; legislation,
allantoin; constituents, 3201863 microsphere properties. 3203098 320342
International Pharmaceutical Abstracts
American Association of Colleges of Pharmacy Subject Index
publications; AACP Pharmacy Deanship Manual, Zhuli; folk medicine, China, 3200398 (8s,10s)-8-(3-Aminopropanoyloxyacetyl)-10-[(2,6-
3204049 y-Aminobutyric acid dideoxy-2-fluoro-a-L- talopyranosyl!)oxy}-
role; pharmaceutical education, 3204056 absorption; intestines, rats, 3204620 -7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-
Task Force on Faculty Resource Development and and BR-16A; memory effects, mice, 3203216 methoxy-5,12-naphthacenedione, see DA-125
Renewal; recommendations, 3203435 interactions; baclofen, absorption, intestines, rats, Aminopterin; voltammetry; spiked serum,
Task Force on Scholarship Definition and 84 3201435
Evaluation; recommendations, 3203424 y-Aminobutyric acids; epilepsy; effects, 3202038 Aminopyrazinones; synthesis; analgesic and anti-
American Association of Retired Persons; health Aminocaproic acid; telangiectasia; hereditary inflammatory effects, mice, rats, 3202073
care reform; patient education, 3201551 hemorrhagic. , therapy failure, 3200131 Aminopyrine; chromatography, liquid; and
American Hospital Association; cases; v. National synthesis; metabolites, urine levels, 3204596
Labor Relations Board, collective bargaining, spermicidal effects, 3205654 Aminosalicylates
3200843 synthesis; colitis; ulcerative, 3205168
American Medical Association; meetings; ‘same ‘effects, 3205654 Crohn disease; therapy, 3205168
resolutions, 3205822 Aminoglutethimide 5-Aminosalicylic acid, see Mesalamine
American Pharmaceutical Association adrenal gland hyperfunction; review, 3205568 Amiodarone
compounding; response, news media, 3201542 spectrometry; serum, 3203877 arrhythmia; geriatrics, review, 3201909; therapy,
meetings; annual, 1994, 3201024 toxicity; hypothyroidism, geriatrics, 3201662 3206404; therapy, risks, benefits, 3200733
protocols; development, 3204213 Aminoglycosides effects; hepatic microsomal enzyme activity,
sexual harassment; guidelines, 3205208 algorithms, 3204937 rabbits, 3202124
standards; duty to warn, 3201502; practice, amikacin; dosage estimation, infectious heart failure; therapy, 3204372
200444 endocarditis, 3204694; liposomes, preparation myocardial infarction; prophylaxis, therapy,
American Psychiatric Association; protocols; methods, 3200028; monitoring, personnel 3201378
bipolar disorder therapy, 3205431 training, 3200060 therapy; aconites poisoning, 3204163
American Society of Consultant Pharmacists and cephalosporins; neutropenia therapy, toxicity; dermatological reactions, 3203545
education, pharmaceutical; continuing, provision antineoplastic toxicity, 3204182 Amiodarone hydrochloride; interactions; sodium
of credits, 3204041 and vancomycin; synergism, S. epidermidis lauryl! sulfate, absorption, 3203606
guidelines; communication, pharmacists, endocarditis, 3201772 Amipaque, see Metrizamide
physicians, 3200523 bacterial infections; parenteral therapy, review, Amiridin; overview, 3204204
history; 25 years, 3203955 3201930 Amiridine, see Amiridin
legislation; health care reform, 3201501 body distribution; estimation, methodology, Amithiozone
American Society of Health-System Pharmacists 3200360 and isoniazid; comparison, isoniazid and rifampin,
guidelines; adverse reactions, a 3203501 cross infection; monitoring, strategy, 3205602 tuberculosis, 3202977
organizations; name change, 3200036 dosage schedules; once daily, 3201904; once tuberculosis; costs, 3205225
protocols; INR, position statement, 3204136; daily, overview, 3200753; once daily, rational Amitriptyline
rational therapy, 3205991 therapy, 3201939; once daily, review, 3201928; depression; comparisons, 3205430
role; hospital pharmacy technicians, 3205997 pharmacy notification, 3205994 immunoassay; fluorescence polarization, blood
American Society of Hospital Pharmacists gentamicin; and metronidazole, vs pefloxacin- levels, 3204600
compounding; response, news media, 3201542 metronidazole, 3201689; and penicillin, pain; therapy, 3204376
Council on Professional Affairs; guidelines, septicemia therapy, neonates, 3200438; prescribing; physicians, Sweden, survey, 3204217
pharmaceutical representatives, 3200043 bacteremia therapy, 3206029; blood level toxicity; overdose, 3205356
organizations; name change, 3200036 monitoring, pediatrics, 3204261; effects, Amitriptyline hydrochloride
standards; drugs, adverse reactions, 3200176 ornidazole concentration, PVC bags, 3200721; overdose; respiratory distress syndrome, 3201651
Americans with Disabilities Act; laws; pharmacokinetics, kidney failure, 3203892; X-ray crystallography; description, 3206508
community pharmacy, 3200904 plague therapy, 3200263; rationa! therapy, Amlodipine
Amides; absorption enhancers; synthesis, 3206511 physician education, 3201194; streptococcal comparison, atenolol; hypertension,
Amidinium salts; reactions; inorganic supports, infections, therapy failure, 3201738; utilization, pharmacodynamics, 3201362
3200328 hospitals, Spain, 3204257 comparison, nicardipine; postmarketing
6-Amidino-2-naphthyl p-guanidinobenzoate gentamicin sulfate; and penicillins, bacterial surveillance, England, 3202803
dimethanesulfonate, see Nafamostat mesylate endocarditis, 3206088; interactions, anti- comparison, nifedipine; pharmacokinetics,
1-Amido-6-aryl-4-(2-furfural)-1,2,4- inflammatory agents, 3202115; lyophilization, pharmacodynamics, 3200191
trihydropyridazine-3-(2H)-ones; synthesis; 3204339; release, polylactide cylinders, 3201238 Amami visnaga
antimicrobial effects, 3204571 netilmicin; chronopharmacokinetics, 3203268; constituents; calcium channel blocking effects,
Amifostine; stability; injections, 3204931 combined therapy vs cilastatin/imipenem, 37
Amikacin 3200154 khellin; HPLC, 3200402
blood levels; monitoring, personnel training, netilmicin sulfate; nanoparticles, preparation, visnagin; HPLC, 3200402
3200060 3200210 Ammonia detoxicants; lactulose; therapy,
dosage; estimation, computer models, infectious paromomycin; intestinal cryptosporidiosis, AIDS, pancreatin toxicity, 3203028
endocarditis, 3204694 3201948; toxicity, 3205072 Amniotic fluid; cosmetics; uses, 3200683
liposomes; preparation methods, 3200028 pharmacokinetics; monitoring, 3206632; Amniotic fluid levels; flecainide; placental
Amiloride monitoring, computer programs, 3206844; transfer, body distribution, 3202645
chromatography, liquid; tablets, 3203253 pediatrics, review, 3206626 Amobarbital; chromatography, liquid; serum,
polyuria; therapy, lithium toxicity, 3200644 streptomycin; adverse reactions, 3200067; plague, 3206597
Amiloride hydrochloride; combination, 3206361; plague therapy, 3200263 Amonafide
furosemide; LC, tablets, 3204581 tobramycin; and piperacillin, comparison, chromatography, liquid; tablets, 3205675
Amino acids ceftazidime, 3203020; initial daily dose, incompatibilities; excipients, stability, 3201298
ademetionine; alone and with beta carotene and calculations, 3200807; interactions, 3205641; Amorolfine; overview, 3202595
selenium, 3201694 liposomes, tissue levels, lungs, rats, 3203623; Amoxapine; toxicity; overdose, 3205356
‘y-aminobutyric acid; absorption, intestines, rats, rational therapy, physician education, 3201194; Amoxicillin
3204620; interactions, baclofen, absorption, rats, toxicity, blood levels, central line sampling and omeprazole; GI diseases therapy, 3202521; H.
3204284 errors, 3201557 pylori, 3206416
arginine; effects, hemodynamics, 3200770 tobramycin, combination, amphotericin B, clindamycin and netilmicin; comparison,
carnitine; therapy, anticonvulsants toxicity, colistin; bioadhesion, dosage forms, 3203091 cilastatin/imipenem, 3200154
pediatrics, 3203009; therapy, valproic acid unit-dose, 3205341 combination, clavulanate potassium; toxicity,
toxicity, 3203165 Aminolevulinic acid 09
L-carnitine; therapy, overview, 3202618 and phototherapy; lasers, skin neoplasms, combination, clavulanic acid; melioidosis therapy,
effects; GI serotonin, 3201987; puerarin solubility, 3204197 3201203; prophylaxis, cost benefit analysis,
3206287 and radiation; mouth neoplasms therapy, 3201120 3204753; utilization, hospitals, Spain, 3204257
enteral nutrition; formulations, trauma patients, 5-Aminolevulinic acid, see Aminolevulinic acid comparison, cefadroxil, nitrofurantoin,
3201190 5-Aminolevulinic acid, see Aminolevulinic acid sulfamethoxazole, combination, trimethoprim;
incompatibilities; fat emulsions, 3205481; Amino-1,4-naphthoquinones; synthesis; anti- cystitis therapy, costs, 3203559
propofol, stability, parenteral nutrition, 3202483 infective effects, 3200314 comparison, ceftriaxone; fever therapy,
injections; microbiological contamination, Aminopeptidases; isolation; mammalian cells, bacteremia, pediatrics, 3203173; fever therapy,
3205935 3206539 infections prophylaxis, pediatrics, 3201725
isatin derivatives; pKa, factors, 3204619 Aminophyiline comparison, erythromycin; chlamydia infections,
L-leucine; water flux, levodopa absorption, combination, scopolamine; tablets, UV pregnancy, 3201168; chlamydia infections
3205691 spectrometry, 3206578 therapy, pregnancy, 3206098
levoglutamide; parenteral nutrition, therapy, effects; pharmacodynamics, immunosuppression, emergency drugs; physicians supply, survey,
3204238 3203748 3203701
neoplasms; [N’-(2-chloroethyl)-N'-nitrosoamino] interactions; cyclosporine, toxicity, seizures, endocarditis; prophylaxis, dosage, dental
carbonyl derivatives, 3202529, 3202530 201775 procedures, 3201729
parenteral nutrition; nitrogen balance, 3204228; pharmacokinetics; methodology, 3203921 interactions; methotrexate, toxicity, 3201216
total, infusion methods, 3200381 release; albumin microspheres, kinetics, 3205147 Lyme disease; protocols, 3205576; therapy,
phenylalanine; release, microparticles, 3200575 toxicity; cardiac, blood levels, geriatrics, 3202966 3200749, 3201924
1104 International Pharmaceutical Abstracts